

DEVELOPMENTAL BIOLOGY

FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure

Alejandra González-Loyola¹, Esther Bovay^{1†}, Jaeryung Kim¹, Tania Wyss Lozano^{1,2}, Amélie Sabine¹, Francois Renevey³, Silvia Arroz-Madeira¹, Alexis Rapin⁴, Tomasz P. Wypych^{5‡}, Giorgia Rota³, Stephan Durot⁶, Dominique Velin⁷, Benjamin Marsland⁵, Greta Guarda⁸, Mauro Delorenzi^{1,2}, Nicola Zamboni⁶, Sanjiv A. Luther³, Tatiana V. Petrova^{1*}

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

The mechanisms maintaining adult lymphatic vascular specialization throughout life and their role in coordinating inter-organ communication to sustain homeostasis remain elusive. We report that inactivation of the mechanosensitive transcription factor *Foxc2* in adult lymphatic endothelium leads to a stepwise intestine-to-lung systemic failure. *Foxc2* loss compromised the gut epithelial barrier, promoted dysbiosis and bacterial translocation to peripheral lymph nodes, and increased circulating levels of purine metabolites and angiopoietin-2. Commensal microbiota depletion dampened systemic pro-inflammatory cytokine levels, corrected intestinal lymphatic dysfunction, and improved survival. *Foxc2* loss skewed the specialization of lymphatic endothelial subsets, leading to populations with mixed, pro-fibrotic identities and to emergence of lymph node–like endothelial cells. Our study uncovers a cross-talk between lymphatic vascular function and commensal microbiota, provides single-cell atlas of lymphatic endothelial subtypes, and reveals organ-specific and systemic effects of dysfunctional lymphatics. These effects potentially contribute to the pathogenesis of diseases, such as inflammatory bowel disease, cancer, or lymphedema.

INTRODUCTION

The lymphatic vasculature is indispensable for the maintenance of plasma and tissue volume, immunosurveillance, and absorption of dietary fat. The importance of lymphatic vessels (LVs) for human physiology and pathology and their implication in some of the most common diseases, such as cancer and cardiovascular and neurodegenerative diseases, are only beginning to be appreciated (1, 2). Therefore, progress in this rapidly expanding field critically depends on increased molecular knowledge of both basic principles of lymphatic vascular organization and function as well as on the pathophysiological consequences of lymphatic dysfunction.

The mature lymphatic vascular network comprises blind-ended capillaries that take up interstitial fluid and cells and collecting LVs (collLVs) that transport the lymph to lymph nodes (LNs) and then back to blood circulation. In agreement with their functions, lymphatic capillaries and collLVs are structurally distinct. Capillary lymphatic endothelial cells (capLECs) display discontinuous cell-cell junctions and scarce basement membrane and have no mural cell coverage. CollLVs are lined by elongated LECs with continuous

cell junctions and are surrounded by basement membrane and contractile smooth muscle cells (SMCs). CollLVs contain numerous intraluminal bileaflet valves, which subdivide collLVs into structural units, called lymphangions, and prevent lymph backflow by ensuring the unidirectional lymph transport (3).

Capillary, lymphangion, and valve LECs (vLECs) display specialized molecular profiles (4, 5). CapLECs express molecules facilitating trafficking of immune cells (CCL21A and LYVE1) (6, 7), while lymphangion LECs produce higher levels of basement membrane components and SMC chemoattractant platelet-derived growth factor β (PDGFB) (8, 9). In line with their exposure to high mechanical stress, vLECs express elevated levels of the mechanosensitive transcription factors FOXC2, GATA2, and NFATC1 (8, 10, 11). CollLVs are physically continuous with the LN lymphatic vascular network. Recent single-cell transcriptomic profiling identified various LN LEC types with distinct molecular features that reflect their specialized roles in immune cell trafficking, antigen presentation, and establishment of tolerance (12).

Specialization of adult LVs into collectors and capillaries is crucial for the functionality of the entire lymphatic vascular bed (3). Multiple regulators of collLV patterning and, especially, lymphatic valve development have been identified (4, 5). However, how the hierarchical organization and function of lymphatic vasculature are maintained throughout life is unknown, as is the role of organ-specific environment in this process. Furthermore, while loss of lymphatic capillaries leads to local tissue fibrosis, inflammation, and impaired immune response (13, 14), the biological consequences of collLV dysfunction beyond defective tissue drainage remain elusive.

Lymph flow–induced forhead transcription factor FOXC2 controls formation of lymphatic valves and specialization of collLVs during embryonic and postnatal development (5, 8, 15). Inactivating mutations in *FOXC2* underlie the lymphedema-distichiasis

¹Department of Oncology, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Epalinges 1066, Switzerland. ²SIB Swiss Institute of Bioinformatics, Lausanne 1015, Switzerland. ³Department of Biochemistry, University of Lausanne, Epalinges 1066, Switzerland. ⁴École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland. ⁵Department of Immunology and Pathology, Monash University, Melbourne 3800, Australia. ⁶Institute of Molecular Systems Biology ETH, Zurich 8093, Switzerland. ⁷Service of Gastroenterology and Hepatology, Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne 1011, Switzerland. ⁸Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera italiana (USI), Bellinzona, Switzerland.

*Corresponding author. Email: tatiana.petrova@unil.ch

†Present address: Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster 48149, Germany.

‡Present address: Laboratory of Host-Microbe Interactions, Nencki Institute of Experimental Biology, Polish Academy of Sciences, 02-093 Warsaw, Poland.

syndrome (LDS) (16), a human hereditary disease of LVs. LDS is characterized by late-onset swelling of legs as a result of defective collLVs and valve function and lymph reflux (17). While lymph stasis and swelling of extremities are features of all hereditary lymphedemas (16), LDS patients uniquely develop ectopic peritoneal lymphoid nodules (17), indicating that loss of *FOXC2* leads to organ-specific immunological defects.

Here, we analyzed mice with LEC-specific inactivation of *Foxc2* to evaluate the impact of defective collLV function on adult homeostasis. Using whole-mount imaging and single-cell transcriptomics, we establish the atlas of adult mesenteric LEC subtypes and show a key role of *Foxc2* in the maintenance of their molecular identities and functions. By global analysis of tissues and investigation of gut microbiota and blood metabolites, we also uncover the importance of collLVs in maintaining both intestinal health and long-range communication of the intestine with lungs.

RESULTS

FOXC2 is necessary for the transport function of the adult lymphatic vasculature

Embryonic and postnatal lymphatic vLECs express high levels of FOXC2, whereas lymphangion LECs have intermediate FOXC2 expression [(5, 8, 11) and fig. S1A]. We investigated FOXC2 expression pattern in adult LVs using a whole-mount approach. Unlike in developing lymphatics, FOXC2 protein was very low in lymphangion LECs of large afferent collLVs, whereas FOXC2^{high} cells were detected among valve leaflet and sinus LECs. FOXC2 was also expressed in small collecting/pre-collecting LVs (precollLVs) in a proportion of leaflet and sinus LECs and in scattered lymphangion LECs (Fig. 1A). Adult collLVs thus have a more restricted pattern of FOXC2 expression as compared to embryonic or early postnatal lymphatics (5, 11), suggesting that FOXC2 may be especially important in the maintenance of small collecting and precollLVs.

In accordance with its expression pattern, early postnatal *Foxc2* inactivation led to disorganization of major collLVs and was lethal within a few days (5). To study whether FOXC2 plays a role in the maintenance of the adult lymphatic vascular network, we analyzed *Foxc2^{fl/β};Prox1-CreERT2* (*Foxc2^{lecKO}*) mice (5), in which LEC-specific loss of *Foxc2* was induced at different time points after birth. Analysis of sorted LECs by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and protein staining of tissues confirmed efficient depletion of *Foxc2* (fig. S1, B to D). *Foxc2* deletion in young adult and adult mice extended the survival compared to newborn *Foxc2^{lecKO}* pups (5), with some mice surviving over 20 weeks after tamoxifen administration (Fig. 1B and fig. S1, E and F). Chronic *Foxc2* deficiency initially led to the development of peritoneal ascites, with the majority of mice displaying increased lung vessel permeability (fig. S1G) and pleural effusion at later time points (Fig. 1, C to E). In agreement with these findings, *Foxc2^{lecKO}* mice had increased body weight compared to their wild-type (WT) counterparts (Fig. 1F).

To further analyze LV functionality, we injected high-molecular weight fluorescein isothiocyanate (FITC)-dextran intraperitoneally and monitored its appearance in the thoracic cavity. Dextran rapidly accumulated in the thoracic duct of WT animals (Fig. 1G), highlighting the active role of LVs in surveying the peritoneal cavity. However, the dye filled multiple branches of intercostal LVs and was present in lungs of *Foxc2^{lecKO}*, but not WT, mice,




Fig. 1. *Foxc2* loss disrupts transport function of adult lymphatics. (A) FOXC2 in adult mesenteric LVs. Green, FOXC2; red, PROX1. Scale bars, 50 μ m. Yellow arrowheads, FOXC2^{high} vLECs; blue arrowhead, FOXC2⁺ lymphangion LECs. (B) Kaplan-Meier curve of WT or *Foxc2^{lecKO}* mice survival. Tamoxifen administration at 3 weeks ($*P < 0.001$; $n = 6$ WT; $n = 7$ *Foxc2^{lecKO}*), 4 weeks ($*P < 0.01$; $n = 3$ WT; $n = 8$ *Foxc2^{lecKO}*), and 5 weeks of age ($*P < 0.01$; $n = 12$ WT; $n = 13$ *Foxc2^{lecKO}*). (C) Computed tomography (CT) image of WT and *Foxc2^{lecKO}* lungs. Yellow arrowhead, fluid accumulation. Scale bar, 0.25 cm. Tamoxifen administration at 5 weeks, analysis at 22 weeks. (D) Normalized WT and *Foxc2^{lecKO}* lung volume. $*P < 0.05$; $n = 4$ WT; $n = 10$ *Foxc2^{lecKO}*. (E) Ascites and pleural effusions at 5 weeks ($n = 11$), 10 weeks ($n = 26$), and 17 weeks ($n = 10$) after *Foxc2* inactivation. (F) Increased weight of *Foxc2^{lecKO}* mice. $*P < 0.05$; $n = 10$ WT; $n = 9$ 16-week depleted *Foxc2^{lecKO}*. (G) Backflow into lungs and intercostal *Foxc2^{lecKO}* LVs following intraperitoneal injection of fluorescein isothiocyanate (FITC)-dextran (green). Orange arrowheads, backflow; blue arrowheads, thoracic duct (TD), lung (L), and heart (H). Scale bars, 2 mm. (H) Backflow in efferent skin *Foxc2^{lecKO}* collecting vessel. Tomato-lectin injection into the inguinal LN (ingLN). Yellow arrowheads, backflow/lymph stasis. axLN, axillary LN. Scale bars, 2 mm. $*P < 0.0001$; $n = 7$ WT; $n = 5$ *Foxc2^{lecKO}* mice. Data are means \pm SD.

indicating extensive backflow and rerouting of lymph in the thoracic cavity (Fig. 1G). Similarly, lymph backflow was observed in dermal collLVs following intranodal injection of labeled Tomato lectin (Fig. 1H). In summary, FOXC2 chronic deficiency in adult mice leads to an initial phenotype in the peritoneal cavity and results in lethality due to fluid accumulation in the thoracic cavity.

Foxc2 deficiency leads to organ-specific immunological response

Pleural effusion was a late symptom of *Foxc2* deficiency, observed the earliest after 10 weeks of *Foxc2* inactivation in 5-week-old mice (Fig. 1E). In contrast, one-third of animals developed chyle stasis in the gut and ascites after only 5 weeks of tamoxifen administration (Fig. 1E), indicating that dysfunction of peritoneal LVs precedes other lymphatic vascular beds. To further investigate the accompanying organ changes, we compared the transcriptomes of WT and *Foxc2*^{lecKO} mesenteries and lungs 10 weeks after *Foxc2* deletion. Unbiased pathway analysis using MSigDB database (18) demonstrated a significant enrichment in immunity-related Gene Ontology (GO) terms, such as “adaptive immune response,” “B cell proliferation,” and “response to interferon gamma (IFN γ)” in the mesentery, but not lungs, of *Foxc2*^{lecKO} mice (Fig. 2A and table S1). The transcriptomics data were further confirmed by flow cytometry analysis of immune cells, which demonstrated an increased proportion of mature B cells, plasma cells, and T cells in the peritoneal, but not pleural washes from mice short-term depleted for *Foxc2* compared to WT mice (Fig. 2B and fig. S2A). Within the mature B cell population, we observed an increased number of conventional B2 cells and a tendency for increase in B1a cells (fig. S2, E and F). No differences in the number of peritoneal macrophages, monocytes, neutrophils, or eosinophils were observed (fig. S2, E and F). Lymphocyte accumulation in peritoneal, but not pleural, cavity of *Foxc2*^{lecKO} mice was also observed at a later time point (16 weeks after *Foxc2* depletion) (Fig. 2C). A proportion of long-term depleted *Foxc2*^{lecKO} mice presented increased blood levels of immunoglobulin M (IgM; fig. S3), in agreement with increased peritoneal B cell number and activation.

Fat-associated lymphoid clusters (FALCs) are tertiary lymphoid tissues associated with visceral fat. They survey body cavities for contaminants and act as first-line responders during cavity inflammation (19, 20). To analyze the status of peritoneal FALCs, we stained the omentum of *Foxc2*^{lecKO} and WT mice for the global hematopoietic cell marker CD45. Omental FALCs were strongly enlarged in both short- and long-term *Foxc2*-depleted mice (Fig. 2, D and E, and fig. S2, B and C). Only a tendency toward increased size and number of mesenteric FALCs was observed in *Foxc2*^{lecKO} mice (fig. S4). This is probably due to a more prominent disruption of omental LVs in *Foxc2*^{lecKO} mice (see below) and a role of omental FALCs as filters for the peritoneal fluid components (20). Defective lung lymphatic function in *Clec2*^{-/-} mice is known to generate abundant bronchus-associated lymphoid tissues (21). However, *Foxc2*^{lecKO} mice developed these lung tertiary lymphoid tissues only at a late stage, which agrees with the delayed onset of pulmonary dysfunction (fig. S2D). Together, these data designate ongoing inflammation in the peritoneal cavity as an early and lasting consequence of lymphatic *Foxc2* deficiency.

Defective capillary lymphatic vascular function leads to LN hypoplasia due to reduced delivery of antigens and antigen-presenting cells and absence of lymph flow (22). The arrest of embryonic collLV development is known to prevent LN expansion (23). However, the effects of defective collLV function on adult LNs are not fully understood (24). Therefore, we analyzed the size of LNs in *Foxc2*^{lecKO} and WT mice. Unexpectedly, inguinal and popliteal LNs were significantly larger in *Foxc2*^{lecKO} mice, while the size of axillary and brachial LNs was comparable in *Foxc2*^{lecKO} and WT animals (Fig. 2F). Mesenteric LN (mLN) was not altered in *Foxc2*^{lecKO} mice (fig. S5). This result may be explained by the fact that the mLN filters the intestinal lymph, and therefore, it is likely intrinsically protected




Fig. 2. *Foxc2* deficiency generates organ-specific immune response. (A) Pathways enriched in transcriptomes of 10-week depleted *Foxc2*^{lecKO} versus WT mesenteries. $n = 3$ WT; $n = 4$ *Foxc2*^{lecKO}. NES, normalized enrichment score. Asterisks: Adjusted P value ≤ 0.05 . (B) Increased percentage of CD45⁺B220⁺CD19⁺ B cells, CD45⁺B220⁺CD19⁺GL7⁺CD138⁺ plasma cells, and CD45⁺CD90⁺CD19⁺ T cells in the peritoneal, but not pleural cavity of *Foxc2*^{lecKO} mice. $*P \leq 0.05$; $n = 4$ WT; $n = 4$ *Foxc2*^{lecKO}. n.s., not significant. (C) Total lymphocyte number in the peritoneal and pleural cavities of WT and long-term depleted *Foxc2*^{lecKO} mice. $*P < 0.05$; $n = 14$ WT; $n = 12$ *Foxc2*^{lecKO}. (D) Increased size, but not number, of omental FALCs after short-term, 5-week *Foxc2* depletion. Green, CD45; blue, CD31. Scale bars, 400 μ m. $*P < 0.05$; $n = 4$ WT; $n = 3$ *Foxc2*^{lecKO}. (E) Increased size, but not number, of omental FALCs after long-term *Foxc2* depletion. Green, CD45; blue, CD31. Scale bars, 400 μ m. $*P < 0.01$; $n = 8$ WT; $n = 4$ *Foxc2*^{lecKO}. (F) Normalized weights of popliteal (popLN), inguinal (ingLN), axillary (axLN), and brachial (BrLN) LNs 16 weeks after *Foxc2* deletion. $*P < 0.05$; $n = 12$ WT; $n = 7$ *Foxc2*^{lecKO} mice. Scale bars, 2 mm. Data are means \pm SD.

against inflammatory insults such as bacteria (25). Mesenteric lymphadenopathy has been described only in models receiving a high dose of pathogen insult (26). On the other hand, intestinal lymph likely partially bypasses the mLN due to leakage from mesenteric LVs and by redirection of flow. Together, our results indicate that chronic deficiency in *Foxc2* impairs adult lymphatic draining function and leads to selective peritoneal inflammation and enlargement of lower body peripheral LNs, thus indicating organ-specific alterations upon FOXC2 loss.

Foxc2 inactivation disrupts hierarchical organization of the lymphatic network in an organ-specific manner

We next investigated the impact of *Foxc2* inactivation on the lymphatic vascular network patterning in different organs. In agreement with its expression pattern, *Foxc2* depletion led to degeneration and shortening of valve leaflets in skin and mesenteric LVs 16 weeks after tamoxifen administration (Fig. 3, A and B), as determined by staining for the valve leaflet marker laminin- $\alpha 5$ (27). However, the total number of valve sites in both tissues was not altered (fig. S6, A and B), indicating that *Foxc2* ablation affected only partly the valve architecture, which is in agreement with its restricted expression pattern in valve leaflet and sinus adult LVs compared to younger animals (Fig. 1A). Lymphangion LECs in both dermal and mesenteric collLVs acquired a more rounded shape, and in a proportion of mice, dilated collectors with oak leaf-shaped LECs were observed (fig. S6, C to E).

Patterning of capillaries was similar in the skin of WT and *Foxc2*^{lecKO} mice (fig. S6F). In contrast, we observed marked changes in the organization of LVs in the peritoneal cavity. In mesentery and omentum, we observed thinning of precollLVs, which at times were completely regressed, leading to isolated lymphatic capillary “islands,” with this phenotype being especially striking in the omentum of *Foxc2*^{lecKO} mice (Fig. 3, C to E). This strong phenotype in omental lymphatics may be due to a direct effect of *Foxc2* deficiency as, unlike in other organs, we observed expression of FOXC2 in some omental capLECs (fig. S7). Given increased intraperitoneal infiltration of T and B lymphocytes in *Foxc2*^{lecKO} mice (Fig. 2B), we analyzed the location of immune cells in relation to LVs. Intralymphatic B220⁺ B and CD3⁺ T cells were rarely detected in WT mice. However, we observed an accumulation of T and especially B lymphocytes, which frequently formed clusters in the *Foxc2*^{lecKO} omental and mesenteric lymphatic capillaries (Fig. 3D and fig. S6G). Although dynamic imaging analysis is further necessary, stagnation of immune cells may be a result of decreased lymph flow. Immune cell accumulation was observed even in completely isolated lymphatic islands (Fig. 3D), suggesting that they continue to produce chemoattractive cues. We also observed immune cell aggregates inside and outside of mesenteric collLVs in *Foxc2*^{lecKO}, but not WT, mice (Fig. 3, F and G, and fig. S6H). A selective intra- and peri-lymphatic distribution of lymphocytes seemed to occur in the knockout (KO) collLVs. Valves and, to a lesser extent, other regions of mesenteric collLVs in *Foxc2*^{lecKO} mice harbored intralymphatic aggregates of B cells (Fig. 3F and fig. S6, I and K), whereas perivascular T cells accumulated around disrupted valve areas (Fig. 3G and fig. S6J).

Collectively, these data demonstrate that FOXC2 maintains lymphatic valve integrity in all investigated adult collLVs. They also show that loss of *Foxc2* leads to disruption of hierarchical lymphatic vascular organization and immune cell trafficking in an organ-specific manner. Notably, in peritoneal cavity tissues, in addition to valve loss, we observed regression of small collecting and precollLVs, resulting in disruption of the communication between lymphatic capillaries and large collLVs. Intriguingly, B cells accumulated within LVs, whereas T cells appeared to be attracted to defective valve areas, thus suggesting distinct effects of *Foxc2* deficiency on these two types of lymphocytes.

Intestinal lymphangiectasia, disruption of intestinal epithelial barrier, and gut microbiota translocation in *Foxc2*^{lecKO} mice

One puzzling macroscopic phenotype of *Foxc2*^{lecKO} mice was the selective enlargement of inguinal and popliteal LNs (Fig. 2F).




Fig. 3. *Foxc2* inactivation disrupts hierarchical organization of lymphatic network in an organ-specific manner. (A) Lymphatic valve leaflet degeneration in dermal vessels of 16-week depleted adult *Foxc2*^{lecKO} mice ears. Pink, CD31; white, LAMA5. Yellow arrowhead, degenerated valve. Scale bars, 30 μ m. Quantification of valves with mature semi-lunar shape in WT and *Foxc2*^{lecKO} mice. * $P < 0.001$; $n = 5$ WT; $n = 6$ *Foxc2*^{lecKO}. (B) Lymphatic valve leaflet degeneration in mesenteric vessels of adult *Foxc2*^{lecKO} mice 16 weeks after tamoxifen administration. Staining for VE-cadherin (pink) and LAMA5 (white). Scale bars, 30 μ m. Quantification of valves with mature semi-lunar shape in WT and *Foxc2*^{lecKO} mice. * $P < 0.001$; $n = 5$ WT; $n = 4$ *Foxc2*^{lecKO}. (C) Thinning of lymphatic precollimating vessels in mesentery of long-term depleted *Foxc2*^{lecKO} mice. Green, LYVE1; red, α SMA; white, VE-cadherin. Blue arrow, vessel thinning. Scale bars, 50 μ m. (D) Immune cell accumulation in omental lymphatic capillaries of *Foxc2*^{lecKO} mice. Red, LYVE1; green, CD45. Yellow arrowhead, immune cells; blue arrowhead, LV disruption. Scale bars, 100 μ m. (E) Omental lymphatic capillary disruption in *Foxc2*^{lecKO} mice. Red, LYVE1; white, CD31. $n = 6$ WT; $n = 4$ *Foxc2*^{lecKO} mice. White arrowheads, the point of LV disruption. Scale bars, 200 and 100 μ m in magnified pictures. (F) B cells accumulate within LVs of *Foxc2*^{lecKO} mice. Red, PROX1; green, B220. Blue square, accumulation of B cells within lymphatic valve sinuses. Pink square, accumulation of B cells within lymphangion. Scale bars, 50 and 20 μ m for left and right images. (G) T cells around defective mesenteric lymphatic valves in *Foxc2*^{lecKO} mice. Red, PROX1; green, CD3. Yellow arrowhead, defective valve. Scale bars, 50 μ m.

Further analyses confirmed increased inguinal and popliteal LN cellularity (Fig. 4A) and revealed LN hypertrophy with relatively higher proportion of B cells (Fig. 4A and fig. S8, A to D), while no differences were observed in the immune populations of spleen and bone marrow of *Foxc2*^{lecKO} and WT mice (fig. S8B). Together, these results pointed to persistent activation of selected peripheral LNs in *Foxc2*^{lecKO} mice.

Although inguinal and popliteal LNs do not drain the intestine or peritoneal cavity, we reasoned that loss of lymphatic valves reroutes intestinal lymph, carrying bacteria or bacteria-derived products to peripheral LNs. To study this question, we first analyzed the impact of *Foxc2* inactivation on intestinal LVs. The intestinal lymphatic network comprises lacteals, the lymphatic capillaries that transport dietary lipids from intestinal villi, and submucosal intestinal LVs, draining intestinal lymph to mesenteric collLVs (28). Lacteals, but not lung or skin lymphatic capillaries, were significantly enlarged in *Foxc2*^{lecko} mice, and the intestinal submucosal lymphatic vascular network was dilated and filled with chyle, indicating lymph stasis (Fig. 4, B to E). Moreover, transcripts for T cell marker *Cd8a* and, in

a proportion of mice, for pro-inflammatory cytokines *Il1b* and *Ifng* were up-regulated in the intestine of *Foxc2*^{lecko} mice (Fig. 4F), indicating increased inflammation.

The intestinal epithelial barrier allows uptake of nutrients and water while preventing the entry of microorganisms and toxins. Inflammation is a major trigger for increased intestinal permeability and development of infections, inflammatory bowel disease, and food allergies [reviewed in (25)]. To study the status of the intestinal epithelial barrier, we gavaged *Foxc2*^{lecko} and WT mice with low-molecular weight FITC-dextran and assessed mesenteric LVs 1 hour later. As expected, the fluorescent signal was confined to the intestinal lumen of WT mice, demonstrating an intact intestinal barrier




Fig. 4. Intestinal lymphangiectasia and gut epithelial barrier disruption in *Foxc2*^{lecko} mice. (A) Increased average cell count and frequency of B cells, plasma cells number, and germinal center (GC) B cells in popliteal (popLN) and inguinal (ingLN) LNs of 16-week depleted *Foxc2*^{lecko} mice. * $P < 0.05$; popLN, $n = 4$ WT, $n = 6$ *Foxc2*^{lecko}; ingLN, $n = 5$ WT, $n = 6$ *Foxc2*^{lecko}. (B) Normal ear lymphatic capillary organization in WT and 16-week depleted *Foxc2*^{lecko} mice. White, LYVE1. Capillary diameter normalized to WT mice. n.s.; $n = 4$ WT, $n = 4$ *Foxc2*^{lecko}. Scale bars, 50 μ m. (C) Comparable lung LV organization in WT and 16-week depleted *Foxc2*^{lecko} mice. Red, vascular endothelial growth factor receptor 3 (VEGFR3); blue, 4',6-diamidino-2-phenylindole (DAPI). VEGFR3⁺ area normalized to tissue area and WT values. n.s. $n = 4$ WT, $n = 4$ *Foxc2*^{lecko}. Scale bars, 400 μ m. (D) Intestinal lymphangiectasia in 16-week depleted *Foxc2*^{lecko} mice. Green, LYVE1; red, PROX1; blue, DAPI. Scale bars, 50 μ m. LV area normalized to tissue area and WT values. * $P < 0.01$; $n = 9$ WT; $n = 8$ *Foxc2*^{lecko}. (E) Chyle stasis in 16-week depleted *Foxc2*^{lecko} mice. Scale bars, 1 mm. (F) Increased *Cd8a* in *Foxc2*^{lecko} intestine. RT-qPCR for the indicated transcripts. * $P < 0.05$; $n = 4$ WT, $n = 6$ *Foxc2*^{lecko}. (G) Gavaged FITC-dextran fills mesenteric LVs in *Foxc2*^{lecko} mice (white arrow), but not in WT mice (orange arrow). $n = 6$ WT, $n = 8$ *Foxc2*^{lecko} mice. Scale bars, 0.5 cm. (H) Bacterial translocation to *Foxc2*^{lecko} LNs. 16S rRNA levels in ingLNs and axLNs of WT and *Foxc2*^{lecko} mice, normalized to gut values. * $P < 0.05$; $n = 6$ WT, $n = 5$ *Foxc2*^{lecko}; axLN, n.s., $n = 2$ WT, $n = 2$ *Foxc2*^{lecko}.

(Fig. 4G). However, FITC-dextran accumulated in mesenteric LVs and the surrounding fat in five of eight *Foxc2*^{lecKO} mice (Fig. 4G), indicating intestinal barrier disruption. To study this in more detail, we analyzed the organization of the intestinal epithelial layer in *Foxc2*^{lecKO} and WT mice by staining for the junctional proteins E-cadherin and ZO-1. We observed focal areas of thin intestinal epithelium in the gut of *Foxc2*^{lecKO} mice (fig. S9A). Such phenotype was described previously in models of intestinal injury and represents the sites of epithelial loss covered by the neighboring enterocytes in the process of ongoing mucosal repair (29). These areas lacked ZO-1 expression, indicating locally compromised epithelial barrier (fig. S9B). We also assessed the expression of the antimicrobial peptide Reg3β, which is up-regulated upon gut bacteria colonization and in response to intestinal inflammation or infection to protect the epithelial mucosal surface (30). Increased levels of Reg3β were observed in the crypts of *Foxc2*^{lecKO} mice (fig. S9C), indicating that crypts of *Foxc2*^{lecKO} mice were subjected to increased inflammation.

To investigate the underlying mechanism, we assessed the effects of intestinal lymph on the junctional integrity of intestinal epithelial cells in vitro. We incubated transformed mouse intestinal epithelial cells (31) with freshly collected mouse intestinal lymph, and we assessed the integrity of the cell-cell junctions by staining for E-cadherin and ZO-1. We used dextran sulfate sodium (DSS) known to directly cause intestinal epithelial damage (32) as a positive control. We found that after 16 hours of incubation and similar to DSS, addition of lymph induced loss of cell-to-cell contact, internalization of E-cadherin, and focal loss of ZO-1 staining (fig. S10, A and B). This result indicates that the prolonged contact with intestinal lymph may directly disrupt the intestinal barrier integrity.

A disrupted intestinal barrier can lead to translocation of gut bacteria; therefore, we evaluated the presence of bacterial DNA in the LNs of *Foxc2*^{lecKO} or WT mice by PCR for the 16S ribosomal RNA (rRNA) gene. Bacterial DNA was detected in inguinal, but not axillary, LNs in *Foxc2*^{lecKO} mice, while WT LNs were sterile (Fig. 4H). Analysis of B cell populations in the intestinal lamina propria revealed an increased frequency of IgA⁺ plasma cells in *Foxc2*^{lecKO} mice (fig. S11, A and B), suggesting an augmented humoral response to chronic bacterial exposure. Collectively, these results indicate that loss of lymphatic *Foxc2* impairs normal intestinal barrier function and establishes an abnormal communication of intestine with peripheral LNs.

Foxc2 deficiency alters the gut microbiota and blood metabolome

We next asked whether dysfunctional peritoneal and intestinal lymphatics affect the intestinal microbiota. By performing 16S rRNA gene sequencing analysis of fecal samples, we observed that *Foxc2* inactivation increased the proportion of mice harboring Epsilonbacteraota (Fig. 5A and fig. S12, A and B). Within the phylum Epsilonbacteraota, *Helicobacter hepaticus* was significantly more abundant in *Foxc2*^{lecKO} mice (Fig. 5B), indicating that disrupted lymphatic function induces gut dysbiosis. *H. hepaticus* is a well-studied bacterium known to be implicated in lower bowel inflammation (33), thus indicating that lymphatic vascular dysfunction promotes expansion of colitogenic bacteria.

To study the systemic impact of chronic *Foxc2* deficiency, we analyzed blood metabolites of *Foxc2*^{lecKO} and WT mice using untargeted metabolomics. We observed higher xanthine levels in the blood




Fig. 5. *Foxc2* loss modifies gut microbiome and increases circulating levels of purine metabolites. (A) A higher proportion of *Foxc2*^{lecKO} mice harbor members of the phylum Epsilonbacteraota after 2 months of *Foxc2* depletion. Stacked bar plots: relative bacterial amplicon sequence variant (ASV) abundance at the phylum level 8 weeks ($n = 7$ WT, $n = 6$ *Foxc2*^{lecKO}), 10 weeks ($n = 4$ WT, $n = 8$ *Foxc2*^{lecKO}), and 16 weeks ($n = 7$ WT, $n = 7$ *Foxc2*^{lecKO}) after *Foxc2* deletion. (B) Increased abundance of *H. hepaticus* in *Foxc2*^{lecKO} mice. MA plot: The mean relative bacterial species abundance versus the log-transformed fold change of bacterial species relative abundance in the feces of WT and 8- to 16-week depleted *Foxc2*^{lecKO} mice. Circles, species with calculated fold change abundance; triangles, species with infinite fold difference due to zero abundance. Color intensity proportional to the relative species abundance. $n = 18$ WT, $n = 21$ *Foxc2*^{lecKO}. (C) Increased blood xanthine levels in *Foxc2*^{lecKO} mice. Heatmap: Fold change of induced (red) or reduced (blue) metabolites in *Foxc2*^{lecKO} versus WT mice. $n = 6$ WT, $n = 7$ *Foxc2*^{lecKO} mice. Metabolites ordered by m/z (mass/charge ratio), adjusted $P < 0.05$. On the right, purine metabolic pathway is depicted.

of *Foxc2*^{lecko} mice compared to their WT counterparts. Inosine and inosine monophosphate (IMP), precursors of purine biosynthesis pathways, were also significantly up-regulated in *Foxc2*^{lecko} mice (Fig. 5C and table S2). Together, these results show that chronic *Foxc2* deficiency and impaired lymph transport set in motion a cascade of both local and systemic pathological changes that affect whole-body homeostasis.

Microbiota depletion rescues the intestinal and systemic phenotypes of *Foxc2*^{lecko} mice

To determine the contribution of the altered gut microbiome to the *Foxc2*^{lecko} mice phenotype, we depleted gut microbiota by oral

broad-spectrum antibiotic treatment 8 weeks after *Foxc2* inactivation. 16S rRNA gene sequencing confirmed the depletion of the majority of bacteria phyla (fig. S12C). Notably, treatment with antibiotics significantly improved *Foxc2*^{lecko} mouse survival (Fig. 6A). Antibiotic treatment reduced the number of mice developing pleural effusion and submucosal chyle stasis (Fig. 6, B and C). Further analyses established that oral antibiotics also reduced intestinal dilation of capillary LVs (lymphangiectasia) and enlargement of omental FALCs as well as inguinal and popliteal LNs (Fig. 6, D to F). Last, analysis of plasma metabolites demonstrated reduction of xanthine, inosine, and IMP levels upon antibiotic treatment (fig. S12D). As previously described (34, 35), levels of primary bile acids such as




Fig. 6. Microbiota depletion rescues the phenotype of *Foxc2*^{lecko} mice. (A) Antibiotics improve *Foxc2*^{lecko} mice survival. Treatment scheme and Kaplan-Meier survival curve of untreated and antibiotic-treated (Abx) WT mice and *Foxc2*^{lecko} mice. **P* < 0.05; *n* = 17 WT, *n* = 16 WT + Abx, *n* = 20 *Foxc2*^{lecko}, *n* = 17 *Foxc2*^{lecko} + Abx. (B) Ascites and pleural effusions in untreated and Abx-treated *Foxc2*^{lecko} mice. *n* = 10 *Foxc2*^{lecko}, *n* = 12 *Foxc2*^{lecko} + Abx. (C) Microbiota depletion rescues chyle stasis of *Foxc2*^{lecko} mice. Bright-field pictures, *n* = 7 *Foxc2*^{lecko}, *n* = 12 *Foxc2*^{lecko} + Abx. Scale bars, 1 mm. (D) Intestinal lymphangiectasia in *Foxc2*^{lecko} mice. Green, LYVE1; blue, DAPI. Scale bars, 50 μm. LV area normalized to tissue area. **P* < 0.01; *n* = 9 WT, *n* = 9 WT + Abx, *n* = 5 *Foxc2*^{lecko}, *n* = 7 *Foxc2*^{lecko} + Abx. (E) Microbiota depletion abrogates omental FALC enlargement of *Foxc2*^{lecko} mice. Green, CD45; red, LYVE1. Scale bars, 100 μm. FALC size and number normalized to tissue area in WT and *Foxc2*^{lecko} mice. **P* < 0.001 WT versus *Foxc2*^{lecko}; **P* < 0.01 *Foxc2*^{lecko} versus *Foxc2*^{lecko} + Abx, *n* = 8 WT, *n* = 8 WT + Abx, *n* = 4 *Foxc2*^{lecko}, *n* = 7 *Foxc2*^{lecko} + Abx. (F) Microbiota depletion abrogates enlargement of peripheral *Foxc2*^{lecko} LNs. **P* < 0.01 inguinal LN (IngLN) in WT versus *Foxc2*^{lecko}; **P* < 0.05, popliteal LN (PopLN) in WT versus *Foxc2*^{lecko}, *n* = 12 WT, *n* = 14 WT + Abx, *n* = 7 *Foxc2*^{lecko}, *n* = 10 *Foxc2*^{lecko} + Abx. Data are means ± SD.

cholate and taurocholic acid, as well as cholesterol were increased in plasma upon antibiotic treatment. Because sphingolipids are known to be produced by microbiota (36), their absence may lead to the observed reduced levels of plasma ceramide in antibiotic-treated *Foxc2*^{lecKO} mice (fig. S12D).

We also analyzed whether the cell-intrinsic effects of *Foxc2* depletion on lymphatic vasculature were recovered upon antibiotic treatment. Because defective valves and rounded lymphangion LECs were still observed in antibiotic-treated *Foxc2*^{lecKO} mice (fig. S12, E and F), this indicates that the beneficial effects of antibiotic treatment must be indirect and are due to either reduced infection or inflammatory status. Loss of *Foxc2* did not lead to direct lung bacterial transfer and infection (fig. S13, A and B). We next analyzed the levels of inflammatory cytokines linked to the development of vascular leakage and lung edema, such as interleukin 6 (IL6), interferon γ (IFN γ), and tumor necrosis factor α (TNF α) (37) in antibiotic-treated and control WT and *Foxc2*^{lecKO} mice. Although there was no difference in the levels of these cytokines in the blood of control WT and *Foxc2*^{lecKO} mice, we found much lower levels of IL6, IFN γ , and TNF α in the blood of antibiotic-treated WT and *Foxc2*^{lecKO} mice (fig. S13C). To answer how the same levels of inflammatory cytokines can be detrimental in *Foxc2*^{lecKO}, but not WT, mice, we analyzed the circulating levels of angiopoietin-2 (ANGPT2) in WT and *Foxc2*^{lecKO} animals. We focused on ANGPT2 because it is one of the most strongly induced transcripts in LECs from *Foxc2*^{lecKO} mice in our single-cell RNA sequencing (scRNA-seq) data (see below). In addition, previous studies identified ANGPT2 as a critical factor sensitizing blood endothelial cell (BEC) responses to inflammatory stimuli such as TNF α and lung edema (37, 38). Loss of *Foxc2* resulted in significantly increased circulating levels of ANGPT2 (fig. S13D) that were decreased upon antibiotic treatment. On the basis of these results, we propose that antibiotic treatment promotes the survival of *Foxc2*^{lecKO} mice by decreasing the combined effects of circulating ANGPT2 and inflammatory cytokines on systemic inflammation.

Collectively, these data establish the microbiome as being a major contributor to the pathophysiological phenotype of adult *Foxc2*^{lecKO} mice and highlight the importance of environmental factors in the regulation of organ-specific lymphatic and immunological functions.

Single-cell transcriptome analysis defines molecular features of adult LEC functional subsets

To understand the role of *Foxc2* at the molecular level, we analyzed mesenteric LECs using scRNA-seq 3 weeks after *Foxc2* inactivation and before development of overt lymphatic phenotypes. We sorted CD45⁻ Pdpn⁺ CD31⁺ LECs with low stringency gating to avoid loss of a potentially altered LEC population upon *Foxc2* depletion (Fig. 7A and fig. S14A). Uniform manifold approximation and projection (UMAP) visualization and clustering revealed the presence of LECs, BECs, fibroblasts, SMC/pericytes, and mesothelial cells (fig. S14, B and E). Analysis of differentially expressed genes (DEGs) between *Foxc2*^{lecKO} and WT cells confirmed that the transcriptional changes were highest in LECs, which also demonstrated significant reduction in *Foxc2* expression levels (fig. S14, C and D).

We next analyzed in more detail WT and KO LEC populations expressing transcripts for *CD31*, *Flt4*, and *Prox1* (Fig. 7B). On the basis of previously described markers (4, 5), we identified four major clusters of WT LECs: (i) capillary LEC cluster (*Lyve1*⁺, *Ccl21a*⁺, *Reln*⁺, *Foxc2*^{neg} capLECs), (ii) collecting LEC cluster (*Lyve1*^{neg}, *Ccl21a*^{neg}, *Reln*^{neg}, *Foxc2*^{low} collLECs), (iii) valve LEC

cluster (*Lama5*⁺, *Foxc2*⁺, *Gata2*^{high}, *Nfatc1*^{high}, *Gja4*^{high}, *Ccl21a*^{neg}, *Lyve1*^{neg} vLECs), and (iv) pre-collecting LEC/small collecting LEC cluster (divided into LECs that are *Ccl21a*⁺, *Lyve1*⁺, *Foxc2*^{neg}, and LECs that are *Foxc2*⁺, *Ccl21a*^{neg}, *Lyve1*^{neg}, pre/collLECs). In addition, we observed a small cluster of proliferating *Aurkb*⁺, *Mki67*⁺ LECs (prolifLECs) and a capLEC cluster expressing IFN-induced transcripts, such as *Ifit1* and *Isg15* (lfnLECs; Fig. 7C and table S3).

A high proportion of genes with subset-specific expression were not previously characterized as markers of the respective LEC subpopulations. For example, capLECs exposed to low-magnitude transmural flow expressed the light-touch mechanosensitive ion channel *Piezo2*, whereas the related *Piezo1*, which senses fluid shear stress, was enriched in collLECs and vLECs, which experience higher shear stress in vivo (Fig. 7C) (39). CapLECs expressed high levels of regulators of microtubule dynamics *Stmn2* and *Tppp3* and the decoy receptor for inflammatory chemokines *Ackr2*, highlighting the importance of microtubule cytoskeleton and regulated chemokine signaling in initial lymphatics (Fig. 7C).

CollLECs were enriched in transcripts for secreted growth factors regulating SMC/pericyte and fibroblast proliferation and recruitment (*Tgfa*, *Pdgfb*, *Pdgfa*, *Bmp4*, and *Wnt2*), transforming growth factor- β (TGF- β) co-receptors and TGF- β target genes (*Lrg1*, *Eng*, *Bgn*, and *Fn1*), transcripts encoding regulators of vascular tone (*Edn1* and *eNOS*), and peptide processing (*Anpep*) (Fig. 7C and table S3). Unexpectedly, collLECs expressed BEC markers such as the plasmalemma vesicle-associated protein *Phvap* and *Bmx* and transcripts associated with the regulation of blood coagulation such as *Thbd*, *Procr*, *Vwf*, and *Plat* (Fig. 7C and table S3). Transcripts related to ion homeostasis (*Car8*, *Cla3a1*, and *Slco2a1*) and to lipid metabolism and fatty acid transport (*ApoE*, *Ccdc3*, *Cd36*, and *Fabp4*) were also enriched, pointing to additional new functions of collLECs (Fig. 7C and table S3).

Analysis of GO biological processes revealed enrichment in specific and meaningful biological functions associated with each subset, such as regulation of SMC proliferation and TGF- β signaling for collLECs or IFN signaling for some capLECs (Fig. 7D and table S4). To validate these scRNA-seq results, we performed staining for selected new markers, such as vWF and ANPEP, which confirmed their expression in collLECs (Fig. 7E).

To evaluate the clinical relevance of our scRNA-seq atlas, we examined the expression of genes, mutated in different subtypes of human primary lymphedemas (Fig. 7F) (16). High expression of *Flt4* in capLECs is consistent with lymphatic capillary hypoplasia in *Vegfr3*-haploinsufficient mice and in Milroy disease patients (16). Selective expression of *Met* in collLECs and vLECs predicts defects of collLVs in patients with mutations in *MET* and its ligand hepatocyte growth factor (HGF) (40). Collectively, our single-cell transcriptomic analysis identified at least five adult LEC subsets and revealed their distinct and biologically relevant molecular profiles.

Foxc2 loss modifies the molecular identity of the entire lymphatic vascular network

We next compared *Foxc2*^{lecKO} and WT mesenteric LECs at the single-cell transcriptome level to determine whether *Foxc2* depletion altered cellular identity. Intriguingly, the *Foxc2*^{high} valve and pre-collLECs clusters were almost absent in *Foxc2*^{lecKO} samples, underscoring the essential role of *Foxc2* in their maintenance (Fig. 8A). This finding agrees with our previous observations, demonstrating rapid selective clearance of *Foxc2*-deficient valve cells in early postnatal LVs (5). Unexpectedly, only few cells of the capLEC cluster




Fig. 7. Single-cell transcriptome profiling defines molecular and functional subsets of adult LECs. (A) Workflow of the scRNA-seq experiment. Cells were sorted from mesenteries of 6-week-old WT and *Foxc2^{lecko}* mice 3 weeks after *Foxc2* depletion. *n* = 3 per genotype. (B) UMAP plot of WT and *Foxc2^{lecko}* LECs. Six major clusters of LECs in WT mice and nine major clusters in *Foxc2^{lecko}* mice were identified. (C) Dot plot of known markers (in bold) and selected new genes for WT LEC clusters: capillary (capLECs), collecting (colILECs), precollecting and collecting (pre/collLECs), valve (vLECs), proliferative (prolifLECs), and IFN (IfnLECs). The color code indicates scaled average expression level in each cluster, and the dot size indicates the percent of cells in each cluster expressing the given gene. (D) Bar plots of a subset of GO gene sets that were overrepresented among genes up-regulated in capLEC, colILEC, vLEC, and IfnLEC clusters of WT mice. (E) Expression level per cell (ln[normalized counts + 1]) of the new WT LEC markers *vWF* and *Anpep* overlaid on the UMAP and staining of adult mesenteric lymphatic collLVs and capillaries showing expression of *vWF* or ANPEP (green) and PROX1 (red). Scale bars, 50 μm. (F) Dot plot of expression of hereditary lymphedema-related genes in adult LEC subsets of WT mice. The color code indicates scaled average expression level in each cluster, and the dot size indicates the percent of cells in each cluster expressing the given gene.




Fig. 8. *Foxc2* loss modifies the molecular identity of the entire lymphatic vascular network. (A) *Foxc2* inactivation eliminates *Foxc2*^{high} LECs. *Foxc2* expression per cell (ln[normalized counts + 1]) overlaid on UMAP plot, split by genotype. Square area: *Foxc2* expression in WT LECs. Color code: Scaled average expression level in each cluster; the dot size denotes the percent of *Foxc2*⁺ cells in each cluster. (B) New *Foxc2*^{lecko} immune-related LEC subsets. Expression level per cell (ln[normalized counts + 1]) of the indicated transcripts overlaid on WT or *Foxc2*^{lecko} UMAP plots. (C) Trajectory analysis of WT and *Foxc2*^{lecko} LECs. UMAP was generated independently for each genotype using Monocle3. (D) capLEC and collLEC phenotypes converge upon loss of *Foxc2*. Module score per cell overlaid on UMAP plot, split by genotype. Scores calculated using WT collLECs versus capLECs up- or down-regulated transcripts. Higher score indicates that more signature genes are expressed in a cell. (E) GO terms overrepresented among up-regulated (red bars) or down-regulated (blue bars) LEC cluster KO1 transcripts versus WT capLECs. Vertical lines: Adjusted *P* value = 0.05. (F) Dot plot of markers for the indicated LEC subsets in WT and *Foxc2*^{lecko} LECs. Color code: Scaled average expression level in each cluster; the dot size denotes the percent of cells in each cluster expressing the given gene. (G) LYVE1 and ENG are reexpressed in *Foxc2*^{lecko} collLVs (collecting LVs) or capLVs (capillary LVs). Scale bars, 50 μ m. (H) Increased ANGPT2 (white) and AQP1 (green) in PROX1⁺ (red) *Foxc2*^{lecko} LVs. Scale bars, 50 μ m. (I) LN LEC cells are located in *Foxc2*^{lecko} collLVs. Green, MADCAM1; red, PROX1; white, LYVE1; blue, DNA. Right: Accumulating DAPI⁺ (blue) cells inside the MADCAM1⁺ (green) LVs. Scale bars, 50 μ m.

remained, while a new KO LEC cluster termed “KO1” emerged located between capLECs and collLECs (Fig. 7B). The collecting and remaining KO vLEC clusters were also shifted within their respective transcriptional space (Fig. 7B). Persistence of the vLEC cluster agrees with partial conservation of the valve architecture in adult *Foxc2*^{lecKO} mesenteric LVs (Fig. 3B). Staining for PROX1, which is highly expressed in all vLECs (8, 11), revealed rings of PROX1^{high} cells in *Foxc2*^{lecKO} lymphangions (fig. S1D), reminiscent of early stages of valve formation (11).

We also observed the emergence of two additional new clusters with immune-related phenotypes: LEC cluster “KO2,” characterized by expression of antigen presentation–related transcripts such as *Cd74* and *H2Ab1*, and LEC cluster “KO3” with LN LEC–specific transcripts such as *Itga2b*, *Madcam1*, *Ltb*, and *Marco* (Fig. 8B and table S5) (12).

Foxc2 loss induces LECs toward an inflammatory, profibrotic, and metabolically active phenotype

To model the relationships between different WT and KO LEC populations, we analyzed their transcriptional trajectories using Monocle 3 (41, 42). The analysis of WT LECs indicated that two major populations, collLECs and capLECs, formed discrete networks, with little interconversion between the two phenotypes (Fig. 8C). In contrast, valve and collLECs were connected by a linear trajectory, consistent with their physical proximity (Fig. 8C).

Trajectory analysis of *Foxc2*^{lecKO} LECs revealed a transcriptional proximity and direct link of the remaining capLEC cluster and the new cluster LEC KO1, supporting the notion that KO1 LECs originate from capLECs. Analyses of collLEC and capLEC signatures derived from the WT transcriptomes demonstrated that KO collLECs acquired some capLEC traits (Fig. 8D). Unexpectedly, capillary-derived KO1 LECs gained the expression of multiple collLEC markers, such as *Pdgfb*, *Plvap*, and *Eng* (Fig. 8F). Staining for lymphatic capillary marker LYVE1 and ENG confirmed these observations (Fig. 8G). Together, these results indicate that *Foxc2* inactivation leads to emergence of convergent cell populations with mixed capLEC and collLEC identities.

Analysis of GO biological processes enriched in *Foxc2*^{lecKO} versus WT LECs revealed activation of pathways related to inflammation, TGF- β signaling, and lipid metabolism (Fig. 8E and fig. S15A), indicating the acquisition of inflammatory, pro-fibrotic, and metabolically active phenotypes. Of note, the GO term “response to bacterium” was among the top enriched pathways, consistent with the bacterial translocation we observed in *Foxc2*^{lecKO} animals (Fig. 8E and fig. S15A).

Relevant transcriptional changes were observed in all *Foxc2*^{lecKO} subsets (table S6). Overall, in comparison to WT capLECs, the KO1 LEC cluster was characterized by higher expression of transcripts for extracellular matrix components (*Fn1*, *Col4a2*, and *Tnc*), TGF- β co-receptors and target genes (*Eng*, *Fn1*, *Id1*, *Id3*, and *Thbs1*), SMC chemotactic growth factor *Pdgfb*, coagulation cascade (*Plat* and *Procr*), fatty acid transport and metabolism regulators (*Cd36*, *Fabp4*, and *Mgl1*), and antagonistic ligand of Tie receptors *Angpt2* (Fig. 8, F to H, fig. S15B) (43). The increased expression of *Angpt2* in KO LECs validates our finding of increased levels of this molecule in the blood of *Foxc2*^{lecKO} mice (fig. S13D) and its potential role in provoking blood vessel permeability, therefore contributing to animal demise. KO1 LECs, but not WT LECs, expressed transcripts encoding monocyte chemoattractants *Ccl2* and *Ccl7* (Fig. 8F).

There was also a higher proportion of proliferating LECs (1.3% of *Foxc2*^{lecKO} versus 0.3% of WT LECs; fig. S16A), and a subset of *Foxc2*-deficient LECs expressed YAP/TAZ target genes *Ctgf* and *Ankrd1*, thus confirming previous observations of increased TAZ signaling and proliferation in FOXC2-deficient LECs (5).

Foxc2 inactivation resulted in the emergence of two new immune-related clusters KO2 and KO3 (Fig. 7B). KO2 LECs expressed high levels of antigen presentation–related *Cd74* and *H2ab1*, the transcriptional regulator of IFN response *Stat1*, and the cytosolic viral sensor Z-DNA–binding protein 1 (*Zbp1*) (Fig. 8, B and F). KO3 LECs expressed transcripts characteristic of LN LECs (Fig. 8, B and F). LN-like LECs could originate from mLN contamination during sample collection; therefore, we investigated their spatial localization by staining for MADCAM1. We observed well-demarcated areas of MADCAM1^{high} LECs within the collLVs of *Foxc2*^{lecKO} mice (Fig. 8I). Unexpectedly, these areas were associated with intra-lymphatic immune cell aggregates, suggesting cross-talk of collLECs with stagnating lymphocytes in the generation of LN LEC identity.

To establish whether the transcriptional changes observed in *Foxc2*-deficient LECs were recapitulated in another model that displays defective lymphatic valves and flow, we analyzed *Cx37*^{-/-} mice (11). Although both models shared similar primary defects (defective LV valves and lymph flow), *Cx37*^{-/-} mice displayed normal life span and did not develop pleural effusion or peritoneal ascites and had normal body weight, contrary to *Foxc2*^{lecKO} mice (fig. S17, A to C). We studied whether transcriptional changes observed in LECs upon *Foxc2* depletion were also induced in mesenteric LECs of *Cx37*^{-/-} mice. Representative genes strongly up-regulated upon *Foxc2* loss were not up-regulated in *Cx37*^{-/-} LECs compared to WT LECs (fig. S17, D to F).

In summary, single-cell transcriptome profiling of *Foxc2*^{lecKO} LECs demonstrated that continuous *Foxc2* expression is crucial for maintaining their specialized phenotypes and revealed an intriguing inflammatory and pro-fibrotic phenotype together with the emergence of new subsets of cells with LN and immune response traits (fig. S18).

DISCUSSION

Major progress has been made in understanding LEC developmental origins and embryonic lymphangiogenesis (4). However, less attention has been paid to the importance of the maintenance mechanisms of adult LVs. An important current challenge is to understand such mechanisms and the role of LVs in coordinating the interactions between different organs to sustain the organism’s physiological health. Here, we analyzed a mouse model with LEC-specific inactivation of *Foxc2* presenting multiple systemic alterations, and we report a broad analysis of the role of collLV functions in adult homeostasis.

Organ-specific lymphatic vascular defects by loss of Foxc2 in adulthood

FOXC2 plays a crucial role in specialization of capillaries and collLVs during embryonic and postnatal development (5, 8, 11, 15). Our current results extend these observations by showing that continuous expression of FOXC2 is necessary for the maintenance of lymphatic valves and directional lymph flow in all vascular beds throughout life. We also report markedly organ-specific physiological repercussions of systemic LEC-specific *Foxc2* deficiency, namely, in the peritoneal cavity and intestine followed by pleural effusion and

animal demise (fig. S19), while the cutaneous lymphatic vascular network was less affected. In particular, *Foxc2*^{lecKO} mice develop expansion of FALCs and selected peripheral LNs, as a result of ongoing peritoneal inflammation and rerouting of intestinal lymph. LDS patients develop peritoneal lymphoid aggregates (17) and have enlarged inguinal LNs (ingLNs) (44), indicating that loss of intestinal lymph compartmentalization is also a part of human pathology.

Our observations highlight the distinct needs and impact of the microenvironment on the maintenance of adult organ-specific lymphatic vasculatures. Maintenance of adult intestinal lacteals, but not dermal capillaries, requires continuous vascular endothelial growth factor receptor 3 (VEGFR3) stimulation (45, 46). In addition, lack of the adherens junction protein VE-cadherin in adult LECs leads to fragmentation of intestinal lacteals and mesenteric, but not dermal, collLVs (47). Higher lability of intestinal/peritoneal LVs could be due to their distinct developmental origin, which potentially programs lower expression of junctional LEC components (47), higher microenvironmental levels of lymphangiogenic factors, and/or exposure to organ-specific immune cells or extracellular matrix components. Also, intestinal lymph transports dietary fat and associated bacterial lipopolysaccharides (LPS) and fat-derived free fatty acids have been shown to increase lymphatic vascular permeability (48). Thus, developmentally programmed features of organ-specific lymphatics and microenvironmental cues must have combinatorial impact on the different outcome of the lack of lymphatic genes in different body compartments.

Role of collLVs in organ-specific lymph compartmentalization and organ-to-organ communication

On the organ level, lymphatic *Foxc2* deficiency led to a compromised intestinal epithelial barrier, dysbiosis, and expansion of colitogenic bacteria in the gut, increased translocation of gut microbiota to peripheral LNs, and changes in systemic blood metabolites. Moreover, the circulating levels of the antagonistic Tie2 ligand ANGPT2 were increased upon *Foxc2* loss. The absence of microbiota rendered *Foxc2*^{lecKO} mice less susceptible to the loss of FOXC2. Depletion of gut microbiota rescued both local symptoms of intestinal and peritoneal cavity LV dysfunction and development of pleural effusion, resulting in improved overall survival. Antibiotics strongly reduced the levels of inflammatory cytokines IL6, IFN γ , and TNF α (fig. S13C), which were previously shown to synergize with ANGPT2 in the induction of blood vessel inflammation. We therefore envision that a combination of defective lymphatics and inflammatory status leads to lung dysfunction and, finally, animal demise, which can be rescued by antibiotics administration.

Loss of intestinal lymphatic capillary function in *Dll4*- or *Vegfr3*-deficient mice reduced dietary lipid absorption but did not impair intestinal health or result in pulmonary dysfunction (45, 46). These results highlight the central and active role of FOXC2 in intestinal and peritoneal collLVs and, in particular valves, in the maintenance of physiological health of the entire organism, notably through compartmentalization of intestinal lymph and communication with other organs, such as lungs.

Dysfunctional collLVs affect microbiota and blood metabolites

A pioneering study showed that acute intestinal infection with *Yersinia pseudotuberculosis* has long-term effects on the gut, inducing inflammation that leads to leaky mesenteric lymphatics. This prevents

dendritic cell trafficking to mLNs, leading to compromised immune mucosal tolerance (26). Our data show that dysfunctional collecting lymphatics provoke immune dysregulation, which may facilitate the alteration and translocation of microbiota, and therefore initiate a feedback loop, further reinforcing lymphatic vascular dysfunction upon *Foxc2* loss.

Intestinal infection has been suggested to be a driver of Crohn's disease pathogenesis, and similar postinfection-like symptoms are observed in such patients (49). Long-term intestinal collLV dysfunction could therefore be a driver of intestinal bowel disease. Moreover, the mesentery of Crohn's disease patients, where the flow of lymph is known to be altered, has been shown to harbor tertiary lymphoid organs (50).

Intestinal inflammation has been shown previously to disrupt the intestinal barrier and generate dysbiosis through a plethora of effects, such as increased secretion of cytokines, chemokines, and lipid-derived mediators (e.g., prostaglandins and leukotrienes) that attract and activate macrophages and neutrophils and alter the gut oxidative and metabolic environment affecting commensal growth (51). Although we do not know what causes the increased abundance of *H. hepaticus* in *Foxc2*-deficient mice, based on our data, we propose that chylomicron-rich lymph stagnation may represent an initial event leading to focal intestinal barrier damage. This damage would lead to increased intestinal inflammation and generate a further vicious cycle that could promote bacterial dysbiosis. A reverse transport of interstitial protein- and lipid-rich fluid to the gut lumen, which may alter the microbiota composition, is another potential contributing factor. Moreover, future studies will be needed to decipher whether an impaired antigen presentation response could be implicated in the increased abundance of *H. hepaticus*.

Changes in composition and function of the gut microbiota are closely related to the progression of metabolic and chronic diseases (52). Here, lymphatic loss of *Foxc2* led to alteration of purine metabolism, as we detected elevated levels of the final product of purine degradation xanthine in the blood of *Foxc2*^{lecKO} mice. This rise was prevented upon depletion of microbiota. The source and pathological significance of higher blood xanthine in our model needs to be investigated in the future. Of interest, pathological stress-induced CD4⁺ cells are a major source of plasma xanthine in mice (53). Thus, lymphatic *Foxc2* deficiency could potentially affect peripheral CD4⁺ cells to produce high levels of xanthine. Another potential driver of increased purine metabolites in the blood of *Foxc2*^{lecKO} mice could be gut dysbiosis. *H. hepaticus* infection in immunodeficient mice has been previously related to changes in numerous serum metabolome pathways, including purine metabolites (54). A recent paper has shown that specific gut microbiota species potentiate checkpoint blockade immunotherapy through production of inosine and activation of antitumor T cells (55). Increased xanthine production in *Foxc2*^{lecKO} mice may therefore have a systemic effect on immune cells. Our strategy of analyzing blood metabolome in a model of lymphedema-distichiasis may offer a new angle to investigate circulatory biomarkers of the disease as diagnostic tools.

Molecular LEC subtypes and their relevance for human diseases

Single-cell transcriptome profiling uncovered molecular features for various adult LEC subtypes. CapLECs express genes for environmental sensing, microtubule dynamics, and chemokine signaling, highlighting that LECs directly communicate with the interstitial space

for immune cell trafficking. A cluster of capLECs with high IFN signaling may represent cells that closely interact with or recently encountered transmigrating IFN-producing immune cells.

In line with their role in lymph transport, collLECs produced higher levels of transcripts encoding basement membrane components and proteins regulating SMC differentiation, recruitment, and contractility. Their unexpected expression of multiple BEC markers underscores the plasticity of adult endothelial cell populations and suggests the potential for LEC-to-BEC transdifferentiation. Adult LVs do not transport platelets; however, collLECs express multiple coagulation cascade proteins, therefore suggesting their potential platelet-independent function. Adult collLVs are enveloped in white adipose tissue, and we found them to express multiple fatty acid transport-related genes. Lipid products generated by collLECs may thus regulate lymphatic SMCs and/or nearby adipocytes or used for their own metabolism.

Fifteen genes are already known to be causative for various forms of primary lymphedema; however, many new causative mutations remain to be identified (16). Our survey of LEC subsets and associated stromal subpopulations (Fig. 7 and fig. S14), together with previously published scRNA-seq analyses of endothelial cells, will be useful to make informed predictions about the mechanism of action of lymphedema-associated genes. As one example, collLECs exclusively express the receptor tyrosine kinase MET, mutated in late-onset primary lymphedema (40), suggesting a novel role of HGF/MET signaling in the development and/or function of collLVs.

Foxc2 maintains the identity of the whole lymphatic network

Foxc2 depletion led to disappearance of *Foxc2*^{high} populations (Fig. 8A), and we observed corresponding partial regression of lymphatic valves and precollLVs in vivo (Fig. 3, A to C), highlighting the importance of *Foxc2* for their maintenance. Analysis of valve sites revealed ring-like and focal PROX1⁺ structures, reminiscent of embryonic valve initiation sites [fig. S1D and (11)]. Previous in vitro studies showed that *FOXC2* depletion increases migration of LECs under flow (5). Thus, in the absence of *Foxc2*, at least some valve cells may migrate back to lymphangion regions, recapitulating early steps of valve formation. Increased motility of LECs in small precollLVs, where *Foxc2* is also expressed in lymphangion cells, and in omental capLECs would explain their thinning and disruption.

Emergence of a major new KO1 LEC cluster derived from capLECs is counterintuitive, given low-to-absent expression of *Foxc2* in this compartment (Fig. 8A). However, widespread changes were documented in the embryonic lymphatic vasculature of *Foxc2*-deficient mice (15). Single-cell transcriptome analyses established that *Foxc2* inactivation leads to a major loss of capillary and, to a lesser extent, collecting endothelial cell identities and to their convergence toward a mixed capillary/collecting phenotype (Fig. 8D). Regression of lymphatic capillaries upon VEGFR3/VEGF-C blockade has little impact on the specialization of collLVs (56); thus, our results reveal an unexpected role of collLVs in the maintenance of lymphatic capillary phenotype and function.

Foxc2-deficient LECs acquired an inflamed and pro-fibrotic phenotype. The latter is likely driven by TGF- β signaling, which promotes fibrosis in multiple other contexts. We observed heightened expression of TGF- β co-receptor endoglin and multiple targets and effectors of TGF- β pathways, such as *Fn1*, *Thbs1*, *Id1*, and *Id3* (57, 58), as well as growth factors inducing mural cell

recruitment and proliferation (*Pdgfb* and *Wnt2*) (9, 59). *FOXC2* knockdown in cultured LECs does not induce TGF- β signaling (5). Thus, TGF- β activation in vivo likely reflects cross-talk of *Foxc2*-deficient LECs with other cell types, such as stagnating immune cells and nearby fibroblasts. Our data suggest that TGF- β -dependent tissue fibrosis is an early event in the pathology of LDS and that therapeutic targeting of TGF- β activation may be of interest for LDS treatment.

The transcriptional changes in *Foxc2*-deficient LECs were not recapitulated in another model with defective lymphatic valves and flow, *Cx37*^{-/-} mice (fig. S17). Such difference may be a result of distinct collecting vessel defects of these models. Notably, loss of *Cx37* prevents development of lymphatic valves without affecting collecting vessel LECs (11), whereas *Foxc2*^{lecKO} animals develop degeneration of lymphatic valves and thinning and disruption of vessels, a process that we have previously shown to be associated with increased perivalvular and valvular LEC proliferation and apoptosis and loss of junctional integrity in collecting vessels (5).

Role of collecting LECs in generation of LN LEC identity

Two new single-cell clusters with immune-related phenotypes were observed in *Foxc2*^{lecKO} LECs: KO2, with high expression of antigen presentation- and inflammation-related transcripts, and KO3, expressing LN LEC-specific transcripts (Fig. 8B and table S5). The expansion of LN-like LECs within the collLVs of *Foxc2*^{lecKO} mice was unexpected. A small number of cells with LN LEC phenotype already exist in the WT LEC population (Fig. 8B), suggesting that collLECs are primed for generation of LECs with LN identity. Areas of LN-like LVs contained intralymphatic aggregates of lymphocytes (Fig. 8I). Thus, interaction of collLECs with lymphocytes may generate a feed-forward loop to promote expansion of LECs with LN identity.

In addition to intravascular B cell aggregates, we observed perivascular T cells surrounding defective valves in *Foxc2*^{lecKO} collLVs (Fig. 3, F and G). Lymph that is prone to leak from vulnerable valve sinuses may be triggering signals for FALC formation or LVs themselves secrete factors, such as chemokines that may attract T cells.

In summary, our study sheds light on the fundamental molecular basis of adult lymphatic vascular organization in which *FOXC2* plays a central role. *FOXC2* is needed to maintain the directional transport of lymph, the connection between different lymphatic compartments, and the identity of the whole lymphatic network. Our results also emphasize the role of a correct LV network wiring in preventing systemic pathogen spread. As both local and systemic effects of defective lymph flow can be rescued upon gut microbiota depletion, our results also highlight the role of LVs in ensuring compartmentalized inter-organ communication.

MATERIALS AND METHODS

Study design

This study was designed to identify the mechanisms of lymphatic collecting vessel maintenance and the biological consequences of their impaired function beyond defective tissue drainage to identify potential therapeutic strategies. For this purpose, we used *Foxc2*^{l/l}; *Prox1*-CreERT2 (5) mice. First, we investigated the outcome of adult mice lacking *Foxc2* and their capacity to transport lymph (Fig. 1), we analyzed peritoneal and pleural compartments and the status of LNs (Fig. 2), and we characterized the status of collecting, precollecting,

vessels and lymphatic capillaries in different vascular beds (Figs. 3 and 4). Second, we focused not only on the organ-specific (Fig. 4) but also on the systemic consequences of the loss of *Foxc2* (Fig. 5). Third, we tested the hypothesis that commensal microbiota has an impact on the phenotype observed and that, by its depletion, the phenotype can be restored (Fig. 6). In the last section, we made use of single-cell transcriptomic analysis to decipher the molecular consequences of *Foxc2* inactivation in adult LECs (Figs. 7 and 8).

Mouse procedures

Animal model

All experiments were approved by the Animal Ethics Committee of Vaud, Switzerland. *Foxc2^{fl/fl};Prox1-CreERT2* (5) and *Cx37^{-/-}* mice (60) were bred to at least the tenth generation on C57BL6/J background. For conditional gene inactivation, *Foxc2^{fl/fl}* (WT) and *Foxc2^{fl/fl};Prox1-CreERT2* (KO) adult mice received three intraperitoneal injections of tamoxifen (50 µg/g body weight) in Kolliphor EL (Sigma-Aldrich) every other day. We used sex-matched littermates that were either *Foxc2^{fl/fl}* (WT) or *Foxc2^{fl/fl}Prox1-CreERT2* (KO). For the analysis of survival, mice were treated with tamoxifen at different ages. In all other experiments, gene inactivation was done in 5-week-old mice. WT and *Foxc2^{lecKO}* mice were analyzed from 5 weeks (short-term depletion) to 16 to 17 weeks after the last tamoxifen injection (long-term deletion). All mice used in our experiments were littermates and optimized for sample size and sex matching.

Computed tomography

Thoracic cavity computed tomography (CT) scan images were acquired using an X-RAD 320ix irradiator (Precision X-Ray) to assess pleural effusion status in *Foxc2^{lecKO}* and WT mice. Mice were anesthetized with 2% isoflurane, positioned supine in the animal holder, aligning its longitudinal axis transverse to the image plane. A two-dimensional (2D) prescan image was taken to confirm the animal position and define the boundaries of the region of interest. Tube voltage was 40 kVp (kilovolt peak), and tube current was 3 mA. The scan was operated on three windows that displayed axial, sagittal, and 25 coronal slices. The lung and thoracic cavity volumes were calculated using OsiriX viewer (61). Signal levels were adjusted (WL115, WW300), the edges of the lungs were first defined in the stack images taken, and the volume of the lungs was calculated with OsiriX software. The same method was used to calculate the volume of the whole thoracic cavity, taking as edges the first fifth ribs of the thoracic cavity from the appearance of neck vertebra until the appearance of the spine vertebra. The 3D volume was reconstructed, the region of interest was analyzed to provide its volume, and the ratio of the volume of the lungs and the thoracic cavity was calculated.

Ascites measurements

For peritoneal liquid measurements, a wick method was used, in which a previously weighted 1.5 cm × 1.5 cm Whatman filter paper was inserted in the peritoneal cavity until all the liquid was absorbed. The paper was then weighted, and the difference between the final and initial weight was normalized versus the body weight of the mouse.

Lymphatic function assays

For the analysis of dermal lymph transport, mice were terminally anesthetized and 5 µl of DyLight 594 *Lycopersicon esculentum* (tomato) lectin (1 mg/ml; Vector Laboratories) was injected into the surgically exposed ingLN. For lymph transport from the peritoneal

cavity, 50 µl of 2000-kDa FITC-dextran in phosphate-buffered saline (PBS) (10 mg/ml; Sigma-Aldrich) was injected intraperitoneally. Mice were allowed to move freely in the cage for 30 min before euthanasia. For the evaluation of the intestinal barrier integrity and lymph leakage, mice were gavaged with 150 µl of 4-kDa FITC-dextran (80 mg/ml; Sigma-Aldrich) and euthanized 1 hour later. Images were acquired using a Leica microscope DFC 3000 G camera equipped with LAS X software (Leica Microsystems) and quantified using Photoshop CC v2015.1.2 (Adobe) and ImageJ Fiji software. For the evaluation of lung vascular permeability, mice were injected intravenously with 100 µl of Evans blue (10 mg/ml) 20 min before dissection. After right ventricle intracardiac perfusion with PBS, lungs were collected and weighed and Evans blue was extracted with formamide.

Antibiotic treatment

WT and *Foxc2^{lecKO}* mice were co-housed since weaning age. Eight weeks after tamoxifen administration, mice received enrofloxacin (2.5 mg/ml; Baytril 10%, Bayer) for 2 weeks in drinking water, followed by 6 weeks of amoxicillin (0.8 mg/ml) and clavulanic acid (0.114 mg/ml; Co-Amoxi-Mepha, Mepha) in drinking water.

Staining procedures and image acquisition

Whole mount

Tissues were fixed with 4% paraformaldehyde (PFA), washed with PBS, permeabilized with 0.5% Triton X-100 (AppliChem), and incubated with blocking solution containing 5% donkey serum, bovine serum albumin (BSA; AppliChem), and 0.5% Triton X-100. Tissues were incubated with primary antibodies, followed by secondary antibodies (Thermo Fisher Scientific) for 3 days on rotating platform at 4°C. Tissues were cleared for minimum 3 days at 70 rpm at 4°C in 1.62 M Histodenz (Sigma-Aldrich) and 0.1% Tween 20 (Sigma-Aldrich) and mounted in Histodenz medium supplemented with Hoechst (0.2 µg/ml; Thermo Fisher Scientific). Confocal images represent maximum intensity projection of Z-stacks of single tile scan images.

Cryosection

Tissues were fixed in 4% PFA for 12 hours, equilibrated in 30% sucrose for 48 hours, and embedded in optimal cutting temperature (OCT) compound (Tissue-Tek, Sakura). Cryosections were cut at 8-µm thickness and fixed with 4% PFA, washed with PBS, permeabilized with 0.5% Triton X-100, and incubated with blocking solution followed by antibody staining. Sections were mounted in Fluoromount-G mounting medium supplemented with 4',6-diamidino-2-phenylindole (DAPI; eBioscience).

Paraffin sections

Sections were cut at 5-µm thickness, deparaffinized, and subjected to heat-induced epitope retrieval using low- or high-pH retrieval solutions (DAKO), incubated with antibodies, and mounted in Fluoromount-G mounting medium supplemented with DAPI (eBioscience).

Images were taken using confocal Zeiss Zen v11.0.0.0 (Carl Zeiss) and analyzed using Imaris 8 (v.8.0.2) (Bitplane) and Photoshop CC v2015.1.2 (Adobe) software. Large image tiles (omental tissue pictures) were acquired using a motorized Zeiss time-lapse Axio Observer.Z1 with Zeiss Axiovision v4.8.2.0 software (Carl Zeiss). Bright-field microscope images were taken using a Leica MZ16 microscope with a Leica Microsystems DFC 295 camera and LAS v4.2 software (Leica Microsystems). The antibodies used for immunostaining are listed in table S7.

Quantifications from histological images

Lymphatic valves were quantified manually under a confocal Zeiss Zen v11.0.0.0 (Carl Zeiss). For skin collLV draining, quantification of total collLV length and *Lycopersicon esculentum* (tomato)-lectin-filled collLV length from ingLN to the axillary LN was quantified using Photoshop CC v2015.1.2 (Adobe) and ImageJ Fiji software. For histological analyses, at least three pictures per each sample were taken. LEC's width versus length ratio was quantified in collLVs using ImageJ Fiji software. To measure lymphatic capillary diameter in ear skin, whole-mount pictures of LYVE-1 staining were taken using 10× objective with a Zeiss Zen v11.0.0.0 confocal microscope. Quantifications were performed with ImageJ Fiji software. Pictures of lymphatic vessels in lungs were acquired using an upright Zeiss Axio Imager Z1 using 20× objective. LV area in the lungs was quantified as the VEGFR3⁺ area normalized to the total tissue area using ImageJ Fiji software. For the quantification of LV area in the ileum, images were acquired using Zeiss Axio Imager Z1 and 20× objective. By means of ImageJ Fiji software, the images were transformed into 8-bit and a threshold was set up in the LYVE1 channel to visualize the LVs. The same threshold was kept for all the pictures. The area of LVs was measured and normalized to the corresponding tissue area. For low-magnification pictures and to quantify the area and number of FALCs of the entire omentum and mesenteric branches, an upright Zeiss Axio Imager Z1 using the tile scan and stitching function and the 10× objective was used. FALC quantification was performed with the ImageJ Fiji software, a threshold was fixed for the CD45 channel to visualize immune cell aggregates, and the area of FALCs versus the total area of the tissue was used as output. For the quantification of B220⁺ cells within LVs, ×20 magnification confocal pictures of whole-mount stainings were used. The number of B220⁺ cells was calculated per vessel area using Fiji software; IMARIS software was used to confirm the internal position of the cells in the vessels.

Immune cell analyses

Peritoneal and pleural wash flow cytometry

Washes were obtained by injecting 3% fetal calf serum in PBS, 150 and 70 µl/g of mouse weight in the peritoneal and thoracic cavities, respectively. Red and white blood cells including lymphocytes, monocytes, and granulocytes were quantified using a Mythic 18 Vet hematology analyzer (Woodly). For fluorescence-activated cell sorting (FACS), peritoneal and pleural washes were centrifuged at 1200 rpm at 4°C for 10 min, resuspended in red blood cell (RBC) lysis buffer (eBioscience) for 5 min at room temperature, and washed with FACS buffer (2 mM EDTA and 2% BSA in PBS). Cells were incubated with Fc block (antibody to CD16/32) for 20 min on ice and stained with conjugated antibodies in FACS buffer for 30 min. Biotin-conjugated primary antibodies were detected with fluorochrome-coupled streptavidin. The cell suspension was passed through a 40-µm strainer, and dead cells were excluded using a Zombie Aqua kit (BioLegend). B cells were identified as CD45⁺CD19⁺B220⁺, and T cells were identified as CD45⁺CD19⁺CD90⁺ cells. For plasma cells, following CD19⁺ selection, a second positive selection for CD138 was performed. For detailed analysis of peritoneal immune cells, the following strategy was performed: B cells were identified as CD45⁺B220⁺CD19⁺, B2 cells as CD45⁺CD19⁺B220^{high}, B1 cells as CD45⁺CD19⁺B220^{low}, B1a cells as CD45⁺CD19⁺B220^{low}CD5⁺, B1b cells as CD45⁺CD19⁺B220^{low}CD5⁻, plasma cells as CD45⁺B220⁺CD19⁺CD138⁺IgM⁺, T cells as CD45⁺CD19⁺CD90⁺, neutrophils as

CD45⁺CD19⁻CD3⁻Cd11b⁺Gr1⁺, eosinophils as CD45⁺CD19⁻CD3⁻Gr1⁻Cd11b⁺SiglecF⁺SSCA^{high}, macrophages as CD45⁺CD19⁻CD3⁻Gr1⁻SiglecF⁻Cd11b⁺F4/80⁺, and monocytes as CD45⁺CD19⁻CD3⁻Gr1⁻SiglecF⁻Cd11b⁺F4/80⁻Ly6C⁺. Samples were acquired on an LSR-II (BD Biosciences) with compensation using single-cell staining and analyzed with FlowJo 10.4.2 software (Tree Star Inc.). For flow cytometry analysis, the frequency of each cell type was calculated as percentage among viable CD45⁺ cells. Gating strategies are presented in fig. S2.

LN, spleen, and bone marrow flow cytometry

The spleen, bone marrow from femurs, and popliteal and inguinal LNs were harvested in PBS with 2% serum and mechanically dissociated using 40-µm cell strainers before staining. Briefly, cells were negatively selected for CD11b and CD11c and positively selected for CD19 for B cells, GL7 for germinal center (GC) B cells, and CD3 for T cells. For plasma cells, following CD19⁺ selection, a second positive selection for CD138 was performed. Data were acquired on a FACSCanto (BD Biosciences) with compensations based on single stainings and analyzed with FlowJo 10.4.2 software (Tree Star Inc.). For flow cytometry analysis, the frequency of each cell type was calculated as percentage among viable CD45⁺ cells. This number was then used along with the cellularity to calculate the total cell number for each cell type. Gating strategies are presented in fig. S8.

Intestinal lamina propria flow cytometry

The second half of jejunum and the complete ileum were dissected and flushed with cold PBS. Peyer's patches and mesenteric fat were removed, and the remaining small intestine was cut longitudinally and then washed with cold PBS. Tissue pieces (0.5 to 1 cm) were incubated for 20 min in Dulbecco's modified Eagle's medium (DMEM) (Gibco) containing 10 mM EDTA with gentle stirring at 37°C. The tubes were vigorously shaken every 10 min to remove epithelial cells, intraepithelial lymphocytes, and mucus. The remaining intestinal tissues were incubated for 20 min at 37°C in digestion buffer containing DMEM, 2% serum, Liberase TL (0.2 mg/ml; Roche), deoxyribonuclease (DNase) I (1 U/ml; Invitrogen), and 1% gentamicin with gentle stirring. To favor tissue dissociation, the pieces of intestine were mixed by pipetting up/down several times after 10 and 20 min. Isolated cells in the supernatant were harvested and kept on ice with a 1:1 volume of complete DMEM until the end of the digestion process. In total, three identical digestions were performed for the complete dissociation of the intestine. The cell suspension was passed through a 40-µm strainer, centrifuged for 6 min at 150g at 4°C, and resuspended in FACS buffer (PBS, 2% serum, and 2 mM EDTA). Cells were incubated with Fc block (antibody to CD16/32) for 20 min on ice and stained with conjugated antibodies in FACS buffer for 30 min. Biotin-conjugated primary antibodies were detected with fluorochrome-coupled streptavidin. IgA⁺ plasma cells were selected as CD45⁺F4/80⁻CD11b⁻CD11c⁻FSC-A^{hi}IgA⁺. Data were acquired on an LSR-II (BD Biosciences) flow cytometer with compensations based on single stainings and analyzed with FlowJo 10.4.2 software. The frequency of each cell type was calculated out of all viable CD45⁺ cells found in each sample. Gating strategy is presented in fig. S11.

LN LEC sorting

Inguinal, axillary, brachial, and popliteal LNs from 8-week-old mice deleted for 2 weeks (one injection each week) with tamoxifen (50 µg/g body weight) were collected in complete medium (phenol red-free DMEM and 5% serum). LNs were minced with scissors and digested with collagenase A (1 mg/ml; Roche), DNase (0.1 mg/ml), and dispase II (0.8 mg/ml) in 0.1% BSA in PBS with shaking at 330 rpm for

30 min at 37°C. EDTA (0.5 M) was added in 1:50 volume for 5 min, and the suspension was filtered through 40- μ m strainer and washed twice in complete medium. Cells were blocked with Fc block (antibody to CD16/32) for 10 min and stained for 30 min with CD45, CD31, and podoplanin (PDPN) antibodies coupled with different fluorophores. Single-stain and unstained samples were used as controls. Following exclusion of multiplets and dead cells using DAPI, single CD45⁻ CD31⁺ PDPN⁺ cells were gated and sorted in RLT lysis buffer containing β -mercaptoethanol (RNeasy Micro Kit, Qiagen).

Mesenteric LEC sorting

Whole mesenteries (mLNs were removed) from three WT and three *Foxc2*^{l^{ec}KO} mice were collected 3 weeks after the first tamoxifen injection. Samples were digested for 30 min in digestion buffer containing Hanks' balanced salt solution (calcium-free, Gibco), 2% BSA, 1% penicillin-streptomycin, Liberase TL (0.2 mg/ml; Roche), and DNase I (1 U/ml; Invitrogen) at 37°C with gentle stirring. Samples were then washed in complete medium [phenol red-free DMEM (Gibco) and 5% serum] and incubated for 5 min at room temperature with RBC lysis buffer (eBioscience). Cells were then washed again, blocked with anti-CD16/32 antibodies, and then incubated with conjugated antibodies specific for CD45, CD31, and PDPN. Following exclusion of dead cells using DAPI and/or RedDot1 Far-Red Nuclear Stain reagent (Biotium) and gating on single cells, single CD45⁻ CD31⁺ PDPN⁺ cells were gated and sorted directly in lysis buffer RLT containing β -mercaptoethanol (RNeasy Micro Kit, Qiagen). Gating strategies are presented in figs. S1 and S14.

Cells were sorted on a FACSAria II (SORP) v8.0.1 cell sorter with FACSDiva software (BD Biosciences). All antibodies used for flow cytometry are listed in table S7.

Biochemical analyses

LPS concentration was determined using a Limulus amoebocyte lysate assay kit (LAL QCL, Lonza). Tissue extracts in radioimmunoprecipitation assay (RIPA) buffer and serum were diluted in LAL reagent water (1:40) and heated at 75°C for 10 min. An internal LPS control from the kit was included. Serum cytokines IL6, IFN γ , and TNF α were determined by using a LEGENDplex mouse inflammation panel kit (BioLegend) using CytoFlex S1 machine (Beckman Coulter) and analyzed using the BioLegend software provided with the kit. A mouse/rat ANGPT2 enzyme-linked immunosorbent assay (ELISA) (R&D Systems) was used for measurement of ANGPT2 levels. Total IgM levels in blood were determined using an ELISA mouse IgM kit (Thermo Fisher Scientific).

Lymph sampling and in vitro studies

Collection of intestinal lymph from the mesenteric lymphatic duct was performed according to previously described methods (62, 63), with some modifications. Briefly, to facilitate visualization of the lymphatic duct, 8 μ l of olive oil (Sigma-Aldrich) per gram of body weight was administered by oral gavage to mice 1 hour before general anesthesia using 2% isoflurane. The abdomen was opened by midline incision, and the intestine and colon were retracted to the left side of the animal to identify and locate the mesenteric lymphatic duct. Under a microsurgical microscope (OPMI MD with Universal S3 Stand; Carl Zeiss), a 30-gauge needle linked to 0.5-ml syringe (BD Biosciences) was inserted to the lymphatic duct and advanced for 2 to 3 mm. About 10 to 20 μ l of intestinal lymph were obtained from each mouse. Five percent intestinal lymph in complete DMEM was incubated with confluent transformed mouse

intestinal epithelial cells (31) for 16 hours. Cell-cell junctions were analyzed by staining for E-cadherin and ZO-1. Five percent DSS was used as positive control for epithelial cell-cell junction disruption.

Tissue nucleic acid isolation and RT-qPCR

RNA isolation

Tissue samples were washed twice in ice-cold PBS, incubated for 30 min in RNA later solution (Invitrogen), transferred into RLT lysis buffer with β -mercaptoethanol (Qiagen), and snap-frozen on dry ice. Following homogenization with a FastPrep-24 disruptor (MP Biomedicals), the RNA was isolated using the Qiagen RNeasy Plus Mini Kit (Qiagen). RNA concentration and quality were analyzed using 2100 Bioanalyzer (Agilent). In the case of LNs, RNA was amplified using Ovation Pico WTA System V2 (Nugen).

DNA isolation

DNA extraction from tissues was performed by incubating the samples for 2 hours in proteinase K and heated for 15 min at 95°C. This DNA was used as a template for PCR amplification. DNA concentration and quality were assessed using NanoDrop 1000 (Thermo Fisher Scientific).

Reverse transcription quantitative polymerase chain reaction

We used reverse transcriptase First Strand cDNA Synthesis Kit (Roche Diagnostics), StepOnePlus Real-Time PCR instrument (Applied Biosystems), and SYBR Green PCR Master Mix (Thermo Fisher Scientific) for qPCR analyses. Data were analyzed using the comparative C_t ($\Delta\Delta C_t$) method as described by the manufacturer. Gene expression was normalized to the housekeeping gene 18S. RT-qPCR results are shown as fold change over controls. The nucleotide sequences of the real-time qPCR primers used in this study are described in table S7.

Tissue bulk RNA-seq

Tissue preparation and sequencing procedure for bulk RNA-seq

For lungs, the left lobule of lungs was dissected. For mesentery, the mesentery part from ileum and jejunum was entirely dissected and mLN was removed. For both tissues, RNA was isolated as described above (see the "RNA isolation" section). RNA quality check, library preparations, and sequencing reactions were conducted at Lausanne Genomic Technologies Facility (<https://wp.unil.ch/gtf/>). Total RNA samples were quantified using Qubit 2.0 Fluorometer (Thermo Fisher Scientific), and RNA integrity was checked with 4200 TapeStation (Agilent Technologies). All RNAs had an RNA quality number above 7.5. RNA-seq libraries were prepared from 500 ng of total RNA. RNA-seq library preparation used the TruSeq Stranded RNA Library Prep Kit for Illumina by following the manufacturer's recommendations (Illumina). Briefly, enriched RNAs were fragmented for 15 min at 94°C. First- and second-strand complementary DNAs (cDNAs) were subsequently synthesized. cDNA fragments were end-repaired and adenylated at 3' ends, and universal adapter was ligated to cDNA fragments, followed by index addition and library enrichment with limited PCR cycles. Sequencing libraries were validated on the Agilent TapeStation (Agilent Technologies) and quantified by using Qubit 2.0 Fluorometer (Invitrogen) as well as by quantitative PCR (Applied Biosystems). After clustering, the flowcell was loaded on the Illumina HiSeq instrument according to the manufacturer's instructions. The samples were single-end sequenced (150 nucleotides) using HiSeq 4000 SR, each sample being sequenced on three separate lanes to increase coverage per sample.

Image analysis and base calling were conducted by the HiSeq Control Software. Raw sequence data (.bcl files) generated from Illumina HiSeq were converted into fastq files and demultiplexed using Illumina's bcl2fastq 2.17 software (Illumina). One mismatch was allowed for index sequence identification.

Bulk RNA-seq data analysis

Raw sequencing read alignment and count summarization were performed using the bcbio-nextgen pipeline (v.19.03, <https://github.com/bcbio/bcbio-nextgen>). Quality encoding of sequencing reads was converted to Sanger format using seqtk (<https://github.com/lh3/seqtk>). Sequencing reads obtained on the three lanes per sample were concatenated and aligned to the *Mus musculus* genome (mm10) using HISAT2 (v.2.1.0) (64). Sequence alignment map files were converted to binary alignment map files and indexed using SAMtools (v.1.9) (65). Read count summarization at the gene level was performed using the featureCounts method (66) of the Subread package (v.1.6.3) using the mm10 genome annotation.

Subsequent statistical analyses were performed using R (v.3.5.3 and v.3.6.0). Each tissue was analyzed independently from the other tissues. First, counts were filtered to remove undetected genes. Normalization factors were calculated using the trimmed mean of *M* values method (67) implemented in the edgeR package (v.3.28.1) for R. The CQN (68) (v.1.33.0) package for R was used to calculate generalized linear model (GLM) offset values, by providing GC content and longest transcript length of each gene to the cqn function. Percentage of GC and longest transcript length were obtained using the biomaRt (69) (v.2.38.0) package for R. Differential gene expression analysis between KO and WT mice for each tissue was performed by fitting gene-wise negative binomial generalized linear model using the glmFit function of the edgeR package, followed by likelihood ratio tests using the glmLRT function. Genes were considered as significantly differentially expressed at a Benjamini-Hochberg (BH) (70)-adjusted *P* value of <0.05.

Gene set enrichment analysis (GSEA) was performed following the method described by Subramanian *et al.* (18). We tested enrichment against the GO (71, 72) gene sets downloaded from the MSigDB (18) website (v.7.1). This list of gene sets was filtered to remove the ones with less than 40 genes, and log₂(fold change) values were provided as the gene statistic. A normalized enrichment score and associated *P* value were calculated for each gene set by randomizing gene labels 1000 times. A gene set was considered as statistically significant at BH-adjusted *P* value of <0.05.

Single-cell RNA-seq

Cell sorting and sequencing procedure for single-cell RNA-seq

Mesentery LECs were isolated from three WT and three *Foxc2*^{lecKO} samples following the protocol described above (see the "Mesenteric LEC sorting" section). Cells were sorted at 4°C on a Beckman Coulter MoFlo Astrios EQ. The instrument was configured with a 70-µm nozzle at a pressure setting of 60 psi. Viability was evaluated on the sorter and was, on average, 80%. Viable cells were identified as being redDot positive and DAPI negative. The staining was performed for 5 min at room temperature at a 1× redDot concentration and a DAPI concentration of 0.1 µg/ml. Cells were gated as shown in fig. S14.

LECs were recovered in Hank's Balanced Salt solution (HBSS) with 40% serum. A total of 21,000 LECs were sorted, on average, per sample. Of those, an average of 11,000 cells were loaded on a Chromium Next GEM Chip B (10x Genomics). Droplets encapsulating single

cells were generated using the 10x Genomics technology (Single Cell 3' v3 chemistry). Briefly, an emulsion encapsulating single cells, reverse transcription reagents, and cell barcoding oligonucleotides was generated. After the actual reverse transcription step, the emulsion was broken and double-stranded cDNA was generated and amplified in a bulk reaction for 12 PCR cycles. This cDNA was fragmented, a P7 sequencing adaptor was ligated, and a 3' gene expression library was generated by a 14-cycle PCR amplification.

The sequencing libraries were prepared according to the manufacturer's recommendations (Chromium Single Cell 3' GEM Kit v3). Libraries were quantified by a fluorimetric method (Qubit, Thermo Fisher Scientific), and their quality was assessed on a Fragment Analyzer system (Agilent Technologies). Cluster generation was performed with 1.4 nM of an equimolar pool from the resulting libraries, including 10% PhiX spike, using the Illumina HiSeq 3000/4000 PE Cluster Kit reagents (Illumina). Sequencing was performed on two runs in the Illumina HiSeq 4000 using HiSeq 3000/4000 SBS Kit reagents (Illumina) according to Illumina 10x Genomics recommendations at the Lausanne Genomic Technologies Facility (<https://wp.unil.ch/gtf/>). Sequencing data were demultiplexed using the bcl2fastq2 Conversion Software (version 2.20, Illumina) and aligned to the mouse reference genome (mm10) using the 10x Genomics Cell Ranger pipeline (version 3.1.0). A minimum of 33,000 reads/cell were obtained, and 18,271 genes, on average, were detected.

scRNA-seq data analysis

The aggr function of the Cell Ranger pipeline was used to generate a single count matrix including all six WT and KO samples. The filtered feature × barcode matrix was imported into R (v.3.6.0) and subsequently analyzed using the Seurat package (73) for R (v.3.1.5). We filtered the count matrix to retain cells that had between 500 and 5800 genes detected, less than 20% of mitochondrial gene counts, and less than 6% of dissociation-related genes (74) (*n* = 21,962 cells retained). Genes not detected in at least three cells were removed (*n* = 19,054 genes retained). The counts were log-normalized (scale factor = 10,000) and scaled using the NormalizeData and ScaleData functions implemented in the Seurat package. Most variable gene detection and principal component (PC) reduction were performed using the FindVariableFeatures and RunPCA functions using default parameters. Cell clustering of all WT and KO cells was performed using the shared nearest neighbor modularity optimization-based algorithm implemented in the FindNeighbors and FindClusters functions, using 19 PCs and a 0.4 resolution. UMAP dimensionality reduction was performed using the RunUMAP function of the Seurat package with parameters reduction = "pca" and 20 PCs.

Annotation of cell types was performed using known and marker genes of each cluster (fig. S14, B and E) (75, 76). Genes differentially expressed between each cluster (i.e., marker genes) and all other cells were determined using the FindAllMarkers function with parameters log₂ (fold change) threshold = 0.15, test.use = "wilcox". Genes significant with a false discovery rate (FDR)-adjusted *P* value below 0.05 were retained. Within each cluster, genes differentially expressed between WT and KO cells were determined using the FindMarkers function of the Seurat package with default parameters.

The raw counts of cells belonging to clusters 0 (LECs, capillaries), 1 (LECs, lymphangion), 4 (LECs in KO), 11 (proliferating ECs), 12 (LECs, LN-like), and 13 (BECs/LECs) (fig. S14, B and E) were extracted and normalized anew using the same functions as described for all cells using the following modifications: The

percentage of dissociation-related genes was regressed out during scaling; the clustering resolution was set to 0.5; the UMAP dimensionality reduction was generated using 19 PCs.

Subsequent analyses were performed only on LECs defined as *Cd31*⁺, *Prox1*⁺, *Vegfr3*⁺, *Flt1*⁻ cells. Marker genes of each LEC cluster were determined for WT and KO separately, using the FindAllMarkers function with default parameters. Last, genes differentially expressed between WT and KO within each cluster were determined using the FindMarkers function using default parameters.

After determining which genes were specifically differentially expressed between WT capLEC and WT collLEC, we generated a signature score for each cell by using the addModuleScore (77) function implemented in the Seurat package. Two scores were generated for each cell: one for the up-regulated genes and one for the down-regulated genes in WT capLEC cluster versus WT collLEC cluster.

Across the WT LEC subsets, 1947 of 19,054 genes (10.22%) were differentially expressed. Among these DEGs, we identified, on average, 220 LEC subset-specific transcripts, defined as genes with a log₂ fold change value higher than 0.25 in each cluster compared to the other cells and FDR-adjusted *P* value below 0.05 (table S3). Collectively, 887 of 19,054 genes (4.65%) were differentially expressed between WT and *Foxc2* KO LECs. Overrepresentation analysis of GO gene sets for any list of DEGs was performed using the enricher function implemented in the clusterProfiler (v. 3.14.13) package (78) for R, with *P* values adjusted using the BH adjustment method (70). Up-regulated or down-regulated genes were tested separately against the GO biological process gene sets (71, 72) downloaded from the MSigDB database (v. 7.1) (18).

Single-cell trajectory analysis was performed using the Monocle method implemented in the monocle3 (v.0.2.2) (42) package for R. The WT and KO LEC clusters were split, and a new UMAP was regenerated independently for each genotype using the reduce_dimension function of monocle3. We provided the new UMAP coordinates and the cluster label of each cell generated by Seurat to the learn_graph function, otherwise using default parameters.

16S rRNA gene sequencing

Bacterial DNA isolation

One fecal pellet from each mouse was collected into sterile 1.5-ml Biopure tube (Eppendorf) and immediately kept on dry ice and stored at -80°C until further processing. Total bacterial DNA was isolated using the QiaAMP Fast DNA Stool Mini Kit (QIAGEN) according to the manufacturer's instructions. DNA was eluted with 100 μl of AE elution buffer (provided with the kit). DNA was stored at 4°C until being used for the PCR.

16S rRNA gene library preparation and sequencing

DNA was extracted from fecal contents as described above, and the V1-V2 hypervariable regions of 16S rRNA gene were amplified using 27F and 338R universal barcoded primers. The nucleotide sequences were as follows: 27F-5'-AATGATACGCGACCACCGAGATC-TACACTATGGTAATTCCAGMGTTYGATYMTGGCTCAG-3' and 338R-5'-CAAGCAGAAGACGGCATAACGAGATNNNNNNNNNNNNAGTCAGTCAGAAGCTGCCTCCCGTAGGAGT-3' (bold: Illumina adaptor sequences; italic: linkers, NNNNNNNNNNNNN sample-specific MID tag barcodes). PCRs were performed in duplicates in a volume of 20 μl each using an AccuPrime Taq DNA polymerase high-fidelity kit (Invitrogen), 4 μl of template DNA, and 0.44 μl each primer (stock at 10 μM). PCR program was as follows: 3 min at 94°C (initial denaturation), followed by 30 cycles of 30 s

at 94°C (denaturation), 30 s at 56°C (annealing), 1.5 min at 72°C (extension), and 5 min at 72°C (final extension). Duplicates were pooled, and amplicon quantity and size were determined with LabChip GX capillary electrophoresis (Perkin Elmer). PCR products were pooled in equimolar amounts and purified using Agencourt AMPure XP magnetic beads (Beckman Coulter). Sequencing was performed on an Illumina MiSeq platform with MiSeq reagent kit V2-500 (pair-end, 2 × 250) as previously described (79) following the basic protocol for stool samples.

16S rRNA gene sequencing data analysis

A table of amplicon sequence variants (ASVs) was derived from the sequencing reads using the DADA2 pipeline (R package dada2) with the Silva 16S database version 132. ASV filtering, normalization, ordination, and diversity analyses were performed using Genocrunch platform (<https://genocrunch.epfl.ch>). Only samples with >1000 ASVs were considered for downstream analyses. The number of observations per samples was equalized using the rarefaction method with a sampling depth of 21,149 (random sampling without replacement) (R package vegan). Values were converted into per-million per column, and a log transformation was applied [$\log_2(x + 1)$]. ASVs were aggregated at each taxonomic level (sum of ASVs with the same taxonomic classification). Abundances were compared between experimental groups at each taxonomic level using fold change and analysis of variance (ANOVA). Rarefaction curves based on species richness were used to compare diversity between experimental groups, on which an ANOVA was performed at a rarefaction depth of 21,140 counts per sample. To compare the relative abundance of Epsilonbacteraeota at the phylum level, a two-tailed *t* test was performed on ASV proportions (%) using GraphPad Prism 8 software (GraphPad).

Metabolomics

Mandibular blood plasma samples were collected at different time points after *Foxc2* depletion. WT, *Foxc2*^{lecKO}, and antibiotic-treated mice were included. Polar metabolites were extracted from 20 μl of plasma with 180 μl of room temperature 80% methanol. Untargeted metabolomics of extracts was done by flow injection analysis–time-of-flight mass spectrometry on an Agilent 6550 Q-TOF instrument as previously described (80). Mass spectra were recorded from a mass/charge ratio of 50 to 1000 in high-resolution negative ionization mode. Ions were annotated by matching their measured mass with reference compounds derived from the Human Metabolome Database (HMDB 4.0), allowing a tolerance of 1 mDa. Significance was calculated using Student's *t* test and corrected for multiple hypothesis testing with the BH method (70). Ion intensities data are provided in table S2.

Statistical analysis

Data analyses were performed using GraphPad Prism 8 for MacOS (GraphPad). The number of mice analyzed is indicated for each image in the figure legends. For in vivo experiments comparing WT and *Foxc2*^{lecKO} animals, normality tests and two-tailed unpaired Student's *t* test were performed to determine statistical significance between two means. For in vivo experiments comparing control and antibiotic-treated WT and *Foxc2*^{lecKO} animals, we used one-way ANOVA with Tukey post hoc test. Scattered dot plot data are shown as means ± SD, where each single dot represents an individual mouse. *P* value is stated in each figure. Differences were considered statistically significant at *P* < 0.05.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <http://advances.sciencemag.org/cgi/content/full/7/29/eabf4335/DC1>

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

1. T. V. Petrova, G. Y. Koh, Biological functions of lymphatic vessels. *Science* **369**, eaax4063 (2020).
2. G. Oliver, J. Kipnis, G. J. Randolph, N. L. Harvey, The lymphatic vasculature in the 21st century: Novel functional roles in homeostasis and disease. *Cell* **182**, 270–296 (2020).
3. A. González-Loyola, T. V. Petrova, Development and aging of the lymphatic vascular system. *Adv. Drug Deliv. Rev.* **169**, 63–78 (2021).
4. M. H. Ulvmar, T. Mäkinen, Heterogeneity in the lymphatic vascular system and its origin. *Cardiovasc. Res.* **111**, 310–321 (2016).
5. A. Sabine, E. Bovay, C. S. Demir, W. Kimura, M. Jaquet, Y. Agalarov, N. Zangger, J. P. Scallan, W. Graber, E. Gulpinar, B. R. Kwak, T. Mäkinen, I. Martinez-Corral, S. Ortega, M. Delorenzi, F. Kiefer, M. J. Davis, V. Djonov, N. Miura, T. V. Petrova, FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature. *J. Clin. Invest.* **125**, 3861–3877 (2015).
6. G. J. Randolph, S. Ivanov, B. H. Zinselmeyer, J. P. Scallan, The lymphatic system: Integral roles in immunity. *Annu. Rev. Immunol.* **35**, 31–52 (2017).
7. D. G. Jackson, Leucocyte trafficking via the lymphatic vasculature—Mechanisms and consequences. *Front. Immunol.* **10**, 471 (2019).
8. C. Norrmen, K. I. Ivanov, J. Cheng, N. Zangger, M. Delorenzi, M. Jaquet, N. Miura, P. Puolakkainen, V. Horsley, J. Hu, H. G. Augustin, S. Yla-Herttuala, K. Alitalo, T. V. Petrova, FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. *J. Cell Biol.* **185**, 439–457 (2009).
9. Y. Wang, Y. Jin, M. A. Mäe, Y. Zhang, H. Ortsäter, C. Betsholtz, T. Mäkinen, L. Jakobsson, Smooth muscle cell recruitment to lymphatic vessels requires PDGFB and impacts vessel size but not identity. *Development* **144**, 3590–3601 (2017).
10. J. Kazenwadel, K. L. Betterman, C. E. Chong, P. H. Stokes, Y. K. Lee, G. A. Secker, Y. Agalarov, C. S. Demir, D. M. Lawrence, D. L. Sutton, S. P. Tabruyn, N. Miura, M. Salminen, T. V. Petrova, J. M. Matthews, C. N. Hahn, H. S. Scott, N. L. Harvey, GATA2 is required for lymphatic vessel valve development and maintenance. *J. Clin. Invest.* **125**, 2979–2994 (2015).
11. A. Sabine, Y. Agalarov, H. Maby-El Hajjami, M. Jaquet, R. Hagerling, C. Pollmann, D. Bebbler, A. Pfenniger, N. Miura, O. Dormond, J. M. Calmes, R. H. Adams, T. Mäkinen, F. Kiefer, B. R. Kwak, T. V. Petrova, Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. *Dev. Cell* **22**, 430–445 (2012).
12. S. Jalkanen, M. Salmi, Lymphatic endothelial cells of the lymph node. *Nat. Rev. Immunol.* **20**, 566–578 (2020).
13. T. Avraham, S. Daluvoy, J. Zampell, A. Yan, Y. S. Haviv, S. G. Rockson, B. J. Mehrara, Blockade of transforming growth factor- β 1 accelerates lymphatic regeneration during wound repair. *Am. J. Pathol.* **177**, 3202–3214 (2010).
14. R. Huggenberger, S. S. Siddiqui, D. Brander, S. Ullmann, K. Zimmermann, M. Antsiferova, S. Werner, K. Alitalo, M. Detmar, An important role of lymphatic vessel activation in limiting acute inflammation. *Blood* **117**, 4667–4678 (2011).
15. T. V. Petrova, T. Karpanen, C. Norrmen, R. Mellor, T. Tamakoshi, D. Finegold, R. Ferrell, D. Kerjaschki, P. Mortimer, S. Yla-Herttuala, N. Miura, K. Alitalo, Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. *Nat. Med.* **10**, 974–981 (2004).
16. S. Martin-Almedina, P. Mortimer, P. Ostergaard, Development and physiological functions of the lymphatic system—Insights from genetic studies of lymphedema. *Physiol. Rev.* (2021).
17. G. Brice, S. Mansour, R. Bell, J. R. Collin, A. H. Child, A. F. Brady, M. Sarfarazi, K. G. Burnand, S. Jeffery, P. Mortimer, V. A. Munday, Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. *J. Med. Genet.* **39**, 478–483 (2002).
18. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 15545–15550 (2005).
19. C. Benezech, N. T. Luu, J. A. Walker, A. A. Kruglov, Y. Loo, K. Nakamura, Y. Zhang, S. Nayar, L. H. Jones, A. Flores-Langarica, A. McClintosh, J. Marshall, F. Barone, G. Besra, K. Miles, J. E. Allen, M. Gray, G. Kollias, A. F. Cunningham, D. R. Withers, K. M. Toellner, N. D. Jones, M. Veldhoen, S. A. Nedospasov, A. N. J. McKenzie, J. H. Caamano, Inflammation-induced formation of fat-associated lymphoid clusters. *Nat. Immunol.* **16**, 819–828 (2015).
20. S. Meza-Perez, T. D. Randall, Immunological functions of the omentum. *Trends Immunol.* **38**, 526–536 (2017).
21. H. O. Reed, L. Wang, J. Sonett, M. Chen, J. Yang, L. Li, P. Aradi, Z. Jakus, J. D'Armiento, W. W. Hancock, M. L. Kahn, Lymphatic impairment leads to pulmonary tertiary lymphoid organ formation and alveolar damage. *J. Clin. Invest.* **129**, 2514–2526 (2019).
22. S. N. Thomas, J. M. Rutkowski, M. Pasquier, E. L. Kuan, K. Alitalo, G. J. Randolph, M. A. Swartz, Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal lymphatic drainage. *J. Immunol.* **189**, 2181–2190 (2012).
23. E. Bovay, A. Sabine, B. Prat-Luri, S. Kim, K. Son, A. H. Willrodt, C. Olsson, C. Halin, F. Kiefer, C. Betsholtz, N. L. Jeon, S. A. Luther, T. V. Petrova, Multiple roles of lymphatic vessels in peripheral lymph node development. *J. Exp. Med.* **215**, 2760–2777 (2018).
24. H. Shimoda, M. J. Bernas, M. H. Witte, Dysmorphogenesis of lymph nodes in Foxc2 haploinsufficient mice. *Histochem. Cell Biol.* **135**, 603–613 (2011).
25. A. M. Mowat, W. W. Agace, Regional specialization within the intestinal immune system. *Nat. Rev. Immunol.* **14**, 667–685 (2014).
26. D. M. Fonseca, T. W. Hand, S. J. Han, M. Y. Gerner, A. Glatman Zaretsky, A. L. Byrd, O. J. Harrison, A. M. Ortiz, M. Quinones, G. Trinchieri, J. M. Brechley, I. E. Brodsky, R. N. Germain, G. J. Randolph, Y. Belkaid, Microbiota-dependent sequelae of acute infection compromise tissue-specific immunity. *Cell* **163**, 354–366 (2015).
27. E. Bazigou, S. Xie, C. Chen, A. Weston, N. Miura, L. Sorokin, R. Adams, A. F. Muro, D. Sheppard, T. Mäkinen, Integrin- α 9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. *Dev. Cell* **17**, 175–186 (2009).
28. J. Bernier-Latmani, T. V. Petrova, Intestinal lymphatic vasculature: Structure, mechanisms and functions. *Nat. Rev. Gastroenterol. Hepatol.* **14**, 510–526 (2017).
29. A. T. Blikslager, A. J. Moeser, J. L. Gookin, S. L. Jones, J. Odle, Restoration of barrier function in injured intestinal mucosa. *Physiol. Rev.* **87**, 545–564 (2007).
30. H. L. Cash, C. V. Whitham, C. L. Behrendt, L. V. Hooper, Symbiotic bacteria direct expression of an intestinal bactericidal lectin. *Science* **313**, 1126–1130 (2006).
31. E. S. Martin, P. J. Belmont, M. J. Sinnamon, L. G. Richard, J. Yuan, E. M. Coffee, J. Roper, L. Lee, P. Heidari, S. Y. Lunt, G. Goel, X. Ji, Z. Xie, T. Xie, J. Lamb, S. L. Weinrich, T. VanArsdale, R. T. Bronson, R. J. Xavier, M. G. Vander Heiden, J. L. Kan, U. Mahmood, K. E. Hung, Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. *Clin. Cancer Res.* **19**, 2929–2940 (2013).
32. H. S. Cooper, S. N. Murthy, R. S. Shah, D. J. Sedergran, Clinicopathologic study of dextran sulfate sodium experimental murine colitis. *Lab. Invest.* **69**, 238–249 (1993).
33. J. G. Fox, Z. Ge, M. T. Whary, S. E. Erdman, B. H. Horwitz, Helicobacter hepaticus infection in mice: Models for understanding lower bowel inflammation and cancer. *Mucosal Immunol.* **4**, 22–30 (2011).
34. T. Le Roy, E. Lécuyer, B. Chassaing, M. Rhimi, M. Lhomme, S. Boudebouze, F. Ichou, J. Haro Barceló, T. Huby, M. Guerin, P. Giral, E. Maguin, N. Kapel, P. Gérard, K. Clément, P. Lesnik, The intestinal microbiota regulates host cholesterol homeostasis. *BMC Biol.* **17**, 94 (2019).
35. S. Wang, M. Huang, X. You, J. Zhao, L. Chen, L. Wang, Y. Luo, Y. Chen, Gut microbiota mediates the anti-obesity effect of calorie restriction in mice. *Sci. Rep.* **8**, 13037 (2018).
36. E. L. Johnson, S. L. Heaver, J. L. Waters, B. I. Kim, A. Bretin, A. L. Goodman, A. T. Gewirtz, T. S. Worgall, R. E. Ley, Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels. *Nat. Commun.* **11**, 2471 (2020).
37. F. R. Millar, C. Summers, M. J. Griffiths, M. R. Toshner, A. G. Proudfoot, The pulmonary endothelium in acute respiratory distress syndrome: Insights and therapeutic opportunities. *Thorax* **71**, 462–473 (2016).
38. U. Fiedler, Y. Reiss, M. Scharpfenecker, V. Grunow, S. Koidl, G. Thurston, N. W. Gale, M. Witznath, S. Rosseau, N. Suttrop, A. Sobke, M. Herrmann, K. T. Preissner, P. Vajkoczy, H. G. Augustin, Angiopoietin-2 sensitizes endothelial cells to TNF- α and has a crucial role in the induction of inflammation. *Nat. Med.* **12**, 235–239 (2006).
39. J. Wu, A. H. Lewis, J. Grandl, Touch, tension, and transduction—The function and regulation of piezo ion channels. *Trends Biochem. Sci.* **42**, 57–71 (2017).
40. D. N. Finegold, V. Schacht, M. A. Kimak, E. C. Lawrence, E. Foeldi, J. M. Karlsson, C. J. Batty, R. E. Ferrell, HGF and MET mutations in primary and secondary lymphedema. *Lymphat. Res. Biol.* **6**, 65–68 (2008).
41. C. Trapnell, D. Cacchiarelli, J. Grimsby, P. Pokharel, S. Li, M. Morse, N. J. Lennon, K. J. Livak, T. S. Mikkelsen, J. L. Rinn, The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat. Biotechnol.* **32**, 381–386 (2014).
42. J. Cao, M. Spielmann, X. Qiu, X. Huang, D. M. Ibrahim, A. J. Hill, F. Zhang, S. Mundlos, L. Christiansen, F. J. Steemers, C. Trapnell, J. Shendure, The single-cell transcriptional landscape of mammalian organogenesis. *Nature* **566**, 496–502 (2019).
43. L. Eklund, J. Kangas, P. Saharinen, Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems. *Clin. Sci.* **131**, 87–103 (2017).
44. J. B. Kinmonth, J. H. Wolfe, Fibrosis in the lymph nodes in primary lymphoedema. Histological and clinical studies in 74 patients with lower-limb oedema. *Ann. R. Coll. Surg. Engl.* **62**, 344–354 (1980).

45. H. Nurmi, P. Saharinen, G. Zarkada, W. Zheng, M. R. Robciuc, K. Alitalo, VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption. *EMBO Mol. Med.* **7**, 1418–1425 (2015).
46. J. Bernier-Latmani, C. Cisarovsky, C. S. Demir, M. Bruand, M. Jaquet, S. Davanture, S. Ragusa, S. Siegert, O. Dormond, R. Benedito, F. Radtke, S. A. Luther, T. V. Petrova, DLL4 promotes continuous adult intestinal lacteal regeneration and dietary fat transport. *J. Clin. Invest.* **125**, 4572–4586 (2015).
47. R. Hägerling, E. Hoppe, C. Dierkes, M. Stehling, T. Makinen, S. Butz, D. Vestweber, F. Kiefer, Distinct roles of VE-cadherin for development and maintenance of specific lymph vessel beds. *EMBO J.* **37**, e98271 (2018).
48. M. Sawane, K. Kajiya, H. Kidoya, M. Takagi, F. Muramatsu, N. Takakura, Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. *Diabetes* **62**, 1970–1980 (2013).
49. L. Peyrin-Biroulet, F. Gonzalez, L. Dubuquoy, C. Rousseaux, C. Dubuquoy, C. Decourcelle, A. Saudemont, M. Tachon, E. Béclin, M. F. Odou, C. Neut, J. F. Colombel, P. Desreumaux, Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. *Gut* **61**, 78–85 (2012).
50. G. J. Randolph, S. Bala, J. F. Rahier, M. W. Johnson, P. L. Wang, I. Nalbantoglu, L. Dubuquoy, A. Chau, B. Pariente, A. Kartheuser, B. H. Zinselmeyer, J. F. Colombel, Lymphoid aggregates remodel lymphatic collecting vessels that serve mesenteric lymph nodes in Crohn disease. *Am. J. Pathol.* **186**, 3066–3073 (2016).
51. J. M. Allaire, S. M. Crowley, H. T. Law, S. Y. Chang, H. J. Ko, B. A. Vallance, The intestinal epithelium: Central coordinator of mucosal immunity. *Trends Immunol.* **39**, 677–696 (2018).
52. J. Durack, S. V. Lynch, The gut microbiome: Relationships with disease and opportunities for therapy. *J. Exp. Med.* **216**, 20–40 (2019).
53. K. Q. Fan, Y. Y. Li, H. L. Wang, X. T. Mao, J. X. Guo, F. Wang, L. J. Huang, Y. N. Li, X. Y. Ma, Z. J. Gao, W. Chen, D. D. Qian, W. J. Xue, Q. Cao, L. Zhang, L. Shen, C. Tong, J. Y. Zhong, W. Lu, L. Lu, K. M. Ren, G. Zhong, Y. Wang, M. Tang, X. H. Feng, R. J. Chai, J. Jin, Stress-induced metabolic disorder in peripheral CD4⁺ T cells leads to anxiety-like behavior. *Cell* **179**, 864–879.e19 (2019).
54. K. Lu, C. G. Knutson, J. S. Wishnok, J. G. Fox, S. R. Tannenbaum, Serum metabolomics in a *Helicobacter hepaticus* mouse model of inflammatory bowel disease reveal important changes in the microbiome, serum peptides, and intermediary metabolism. *J. Proteome Res.* **11**, 4916–4926 (2012).
55. L. F. Mager, R. Burkhard, N. Pett, N. C. A. Cooke, K. Brown, H. Ramay, S. Paik, J. Stagg, R. A. Groves, M. Gallo, I. A. Lewis, M. B. Geuking, K. D. McCoy, Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. *Science* **369**, 1481–1489 (2020).
56. G. Zarkada, K. Heinolainen, T. Makinen, Y. Kubota, K. Alitalo, VEGFR3 does not sustain retinal angiogenesis without VEGFR2. *Proc. Natl. Acad. Sci. U.S.A.* **112**, 761–766 (2015).
57. M. J. Goumans, Z. Liu, P. ten Dijke, TGF- β signaling in vascular biology and dysfunction. *Cell Res.* **19**, 116–127 (2009).
58. R. Derynck, E. H. Budi, Specificity, versatility, and control of TGF- β family signaling. *Sci. Signal.* **12**, eaav5183 (2019).
59. C. Mill, S. J. George, Wnt signalling in smooth muscle cells and its role in cardiovascular disorders. *Cardiovasc. Res.* **95**, 233–240 (2012).
60. A. M. Simon, D. A. Goodenough, E. Li, D. L. Paul, Female infertility in mice lacking connexin 37. *Nature* **385**, 525–529 (1997).
61. A. Ariani, M. Carotti, M. Gutierrez, E. Bichisecchi, W. Grassi, G. M. Giuseppetti, F. Salaffi, Utility of an open-source DICOM viewer software (OsiriX) to assess pulmonary fibrosis in systemic sclerosis: Preliminary results. *Rheumatol. Int.* **34**, 511–516 (2014).
62. M. Nagahashi, A. Yamada, T. Aoyagi, J. Allegood, T. Wakai, S. Spiegel, K. Takabe, Sphingosine-1-phosphate in the lymphatic fluid determined by novel methods. *Heliyon* **2**, e00219 (2016).
63. B. Banan, Y. Wei, O. Simo, P. Tso, N. N. Abumrad, C. R. Flynn, S. Sundaresan, V. L. Albaugh, Intestinal lymph collection via cannulation of the mesenteric lymphatic duct in mice. *J. Surg. Res.* **260**, 399–408 (2021).
64. D. Kim, B. Langmead, S. L. Salzberg, HISAT: A fast spliced aligner with low memory requirements. *Nat. Methods* **12**, 357–360 (2015).
65. H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis, R. Durbin; 1000 Genome Project Data Processing Subgroup, The sequence alignment/map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
66. Y. Liao, G. K. Smyth, W. Shi, featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923–930 (2014).
67. M. D. Robinson, A. Oshlack, A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol.* **11**, R25 (2010).
68. K. D. Hansen, R. A. Irizarry, Z. Wu, Removing technical variability in RNA-seq data using conditional quantile normalization. *Biostatistics* **13**, 204–216 (2012).
69. S. Durinck, P. T. Spellman, E. Birney, W. Huber, Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).
70. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J. R. Stat. Soc. B. Methodol.* **57**, 289–300 (1995).
71. M. Ashburner, C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P. Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-Tarver, A. Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M. Rubin, G. Sherlock, Gene ontology: Tool for the unification of biology. The gene ontology consortium. *Nat. Genet.* **25**, 25–29 (2000).
72. The Gene Ontology Consortium, The Gene Ontology Resource: 20 years and still GOing strong. *Nucleic Acids Res.* **47**, D330–D338 (2019).
73. T. Stuart, A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W. M. Mauck, Y. Hao, M. Stoekius, P. Smibert, R. Satija, Comprehensive integration of single-cell data. *Cell* **177**, 1888–1902.e21 (2019).
74. S. C. van den Brink, F. Sage, Á. Vértesy, B. Spanjaard, J. Peterson-Maduro, C. S. Baron, C. Robin, A. van Oudenaarden, Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations. *Nat. Methods* **14**, 935–936 (2017).
75. M. Vanlandewijck, L. He, M. A. Mäe, J. Andrae, K. Ando, F. Del Gaudio, K. Nahar, T. Lebouvier, B. Laviña, L. Gouveia, Y. Sun, E. Raschperger, M. Räsänen, Y. Zerb, N. Mochizuki, A. Keller, U. Lendahl, C. Betsholtz, A molecular atlas of cell types and zonation in the brain vasculature. *Nature* **554**, 475–480 (2018).
76. L. Muhl, G. Genové, S. Leptidis, J. Liu, L. He, G. Mocchi, Y. Sun, S. Gustafsson, B. Buyandelger, I. V. Chivukula, Å. Segerstolpe, E. Raschperger, E. M. Hansson, J. L. M. Björkregren, X. R. Peng, M. Vanlandewijck, U. Lendahl, C. Betsholtz, Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination. *Nat. Commun.* **11**, 3953 (2020).
77. I. Tirosh, B. Izar, S. M. Prakadan, M. H. Wadsworth, D. Treacy, J. J. Trombetta, A. Rotem, C. Rodman, C. Lian, G. Murphy, M. Fallahi-Sichani, K. Dutton-Regester, J. R. Lin, O. Cohen, P. Shah, D. Lu, A. S. Genshaft, T. K. Hughes, C. G. Ziegler, S. W. Kazer, A. Gaillard, K. E. Kolb, A. C. Villani, C. M. Johannessen, A. Y. Andreev, E. M. Van Allen, M. Bertagnoli, P. K. Sorger, R. J. Sullivan, K. T. Flaherty, D. T. Frederick, J. Jané-Valbuena, C. H. Yoon, O. Rozenblatt-Rosen, A. K. Shalek, A. Regev, L. A. Garraway, Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* **352**, 189–196 (2016).
78. G. Yu, L. G. Wang, Y. Han, Q. Y. He, clusterProfiler: An R package for comparing biological themes among gene clusters. *OMICS* **16**, 284–287 (2012).
79. A. Rapin, C. Pattaroni, B. J. Marsland, N. L. Harris, Microbiota analysis using an illumina MiSeq platform to sequence 16S rRNA genes. *Curr. Protoc. Mouse Biol.* **7**, 100–129 (2017).
80. T. Fuhrer, D. Heer, B. Begemann, N. Zamboni, High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry. *Anal. Chem.* **83**, 7074–7080 (2011).

Acknowledgments: We thank N. Miura for providing the *Foxc2 fl/fl* mice and the rat anti-Foxc2 antibody. T. Makinen (Uppsala University, Sweden) for sharing *Prox1-CreERT2* mice; L. Sorokin (University of Münster, Münster, Germany) for laminin- $\alpha 5$ antibody; G. Y. Koh (KAIST, Daejeon, South Korea) for angiotensin-2 antibody; C. Beauverd for mouse genotyping, colony maintenance, and immunostainings; J. Laube for participation in FALC and initial intestinal permeability analyses; and B. Petit and M.-C. Vozenin for help with hematology analyzer and CT acquisition and analysis. We thank J. Bernier-Latmani for reading the manuscript and useful discussions. Mouse Pathology, Flow Cytometry, Genomic Technologies Facility (GTF), Animal, and Cellular Imaging Facilities of the University of Lausanne are gratefully acknowledged.

Funding: This work was supported by the Swiss National Science Foundation (CRSII5_177191 to T.V.P. and N.Z.; 31ER30_160674, 31003A-156266, and CRSK-3_190200 to T.V.P.; and 310030_185226/1 to S.A.L.), People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme FP7/2007-2013/ under REA grant agreement 317250 (to T.V.P.), interdisciplinary grant of the Faculty of Biology and Medicine of UNIL (to T.V.P. and D.V.), and two postdoctoral fellowships from the Human Frontier Science Program Organization (LT000074/2019-L to J.K. and LT000633/2020-L to S.A.-M.). Work in the laboratory of G.G. was supported by the Swiss National Science Foundation (310030_185185), the Fondazione San Salvatore, Lugano, and the Novartis Foundation. **Author contributions:** A.G.-L. and T.V.P. planned the study, and T.V.P. supervised the research. A.G.-L. prepared the mouse models, performed the mouse studies, and analyzed the data related to Figs. 1 (A to G), 2, 3 (B to G), 4 (B to H), and 5 to 8 and Figs. S1 (A to F), S2, S3 to S7, and S9 to S19; E.B. contributed to Figs. 1 (B, G, and H), 3A, and 4A and Figs. S1 (B, F, and G), S5A, and S8 and independently reproduced similar data to Fig. 2F; J.K. contributed to Figs. 4G and 6 and Fig. S10; T.W.L. contributed to Figs. 7 and 8 and Figs. S14 to S16 and tables S1 and S3 to S6; A.S. contributed to Fig. 1B and figure preparation; F.R. contributed to Fig. 2B and Figs. S2A and S11; S.A.-M. contributed to Fig. S2 (E and F); A.R. and T.P.W. contributed to Fig. 5 (A and B) and Fig. S12 (B and C); G.R. contributed to Fig. 4A and Fig. S8; S.D. contributed to Fig. 5C, Fig. S12D, and table S2; and A.S., N.Z., D.V., B.M., G.G., M.D., and S.A.L. provided reagents, discussions, and advice on

the study, and A.G.-L. and T.V.P. wrote the paper. All authors read, commented on, and approved the manuscript. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** The scRNA-seq and bulk RNA-seq data generated for this publication have been deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE156320 (<https://ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE156320>). 16S raw sequence data have been deposited in the European Nucleotide Archive (ENA) database with the accession number PRJEB39832. This study did not generate new unique reagents. All other data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.

Submitted 26 October 2020

Accepted 1 June 2021

Published 16 July 2021

10.1126/sciadv.abf4335

Citation: A. González-Loyola, E. Bovay, J. Kim, T. W. Lozano, A. Sabine, F. Renevey, S. Arroz-Madeira, A. Rapin, T. P. Wypych, G. Rota, S. Durot, D. Velin, B. Marsland, G. Guarda, M. Delorenzi, N. Zamboni, S. A. Luther, T. V. Petrova, FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure. *Sci. Adv.* **7**, eabf4335 (2021).

FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure

Alejandra González-Loyola, Esther Bovay, Jaeryung Kim, Tania Wyss Lozano, Amélie Sabine, Francois Renevey, Silvia Arroz-Madeira, Alexis Rapin, Tomasz P. Wypych, Giorgia Rota, Stephan Durot, Dominique Velin, Benjamin Marsland, Greta Guarda, Mauro Delorenzi, Nicola Zamboni, Sanjiv A. Luther and Tatiana V. Petrova

Sci Adv 7 (29), eabf4335.
DOI: 10.1126/sciadv.abf4335

ARTICLE TOOLS

<http://advances.sciencemag.org/content/7/29/eabf4335>

SUPPLEMENTARY MATERIALS

<http://advances.sciencemag.org/content/suppl/2021/07/12/7.29.eabf4335.DC1>

REFERENCES

This article cites 79 articles, 20 of which you can access for free
<http://advances.sciencemag.org/content/7/29/eabf4335#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

Science Advances (ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Advances* is a registered trademark of AAAS.

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).